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INTRODUCTION AND LITERATURE REVIEW 
Introduction 
Serine proteinases are proteolytic enz3mies which have an essential 
catalytic serine. They are peptide hydrolases, and can be grouped into more 
than 20 families (RawHngs and Barrett, 1994). The ch5miotrypsin family, with 
approximately 200 members, includes proteinases involved in digestion, 
coagulation, fibrinolysis, and complement activation. 
Inhibitors of proteolytic enzymes are found in most organisms and may 
have defense and regulatory functions (Laskowski and Kato, 1980). Plants have 
been shown to be important soiirces of proteinase inhibitors; they are usually 
specific for animal proteinases and several have been studied and engineered 
not only for enhanced plant protection against pests but also for use in human 
medical applications. They have been isolated firom plant seeds, leaves, roots 
and tubers (Ryan, 1981). Study of inhibitors and their interactions with target 
enzymes provide information regarding the mechanisms by which inhibitors of 
serine proteinases function, as well as the mechanisms by which enzjnnes 
cataljrze reactions. This information can be further applied to diverse 
applications, e.g., in the treatment of human disease conditions. 
P-Factor Xlla, also known as activated Hageman Factor, is a serine 
proteinase involved in the initiation and progression of the blood coagulation 
pathway. Substrates of such proteinases, after hydrolysis, remain productively 
bound to &azyme for a fractional period of time, acting as "virtual substrates" 
(Robertus et al., 1972). Inhibitors of serine proteinases, through their 
mechanism of action (discussed in detail in Part I) may mimic the virtual 
substrate for extended periods of time, thus serving as a good model for study of 
enzjmie-substrate interaction. 
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Cucurbita maxima trypsin inhibitor V (CMTI-V) is an inhibitor of serine 
proteinases, isolated from pumpkin, with highly specific activity toward P-Factor 
XUg (Erishnamoorthi et al., 1990). It belongs to the Potato I family of small 
serine proteinase inhibitors and also inhibits trypsin and (weakly) 
chymotrypsin. Site-directed mutagenesis of either enzyme or inhibitor allow 
study of the structural and functional importance of individual amino add 
residues within the molecules and contribute to an overall understanding of 
enzjone function. We are interested in studying structural-functional 
relationships in CMTT-V. Although the structure of P-Factor XTEa has not yet 
been determined, structures of homologous proteinases such as kaUikrein (Bode 
et al., 1983), trypsin (Read and James, 1988), and chymotrj^sui (Tsukada and 
Blow, 1985) are available. The structure of CMTI-V is also known and is similar 
to structures of other serine proteinase inhibitors of the Potato I family, e.g., 
chymotrypsin inhibitor from barley (McPhalen and James, 1987) and Elgin C 
from leech (Hyberts et al., 1992, Hipler et al., 1992). The structures of the latter 
inhibitors in complex with target enzymes have also been determined (McPhalen 
and James, 1988; Bode et al., 1986; McPhalen et al., 1985a). These data, in 
addition to analysis of residue conservation within the Potato I family and 
modeling efforts of our own with CMTI-V, allow us to predict possible functional 
importance of residues at certain positions within CMTI-V. 
We focused on two inhibitor positions we believed to be important to 
inhibitor activity. The inhibitor residue at the carboxyl end of the reactive 
(hydrolyzed) bond may play an important role in determining a specific 
conformation of the inhibitor-enzyme complex which we hypothesized to be 
dependent on the presence of a negatively-charged residue at that position. The 
stability of this complex may be the basis of inhibitory, rather than substrate­
like, function (Bode and Huber, 1991). We created the following substitution 
mutants: Asp45Val, Asp45Lieu, Asp45Asn and Asp45Glu, expecting to see a 
decrease in inhibitory activity in aU but the fourth mutant. 
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The third residue amino-terminal to the reactive bond is Val. A 
hydrophobic residue at this position (Val in most cases) is fully conserved among 
all members of the Potato I family (see Table 6). We beheve its hydrophobicity 
may be involved in forcing the backbone into position for formation of a p-sheet 
structure, allowing tighter binding at this area of contact between the inhibitor 
and the enzjrme. It may also increase rigidity of the inhibitor-core structure 
through hydrophobic effects, thereby increasing stabihty of the en23rme-inhibitor 
complex. A bulky side chain in certain conformations might decrease tightness 
of bind (through steric hindrances) and a charged or polar residue might 
increase tightness of bind (either through introduction of additional enzsone-
inhibitor contacts or inhibitor-inhibitor contacts). Several substrates of P-Factor 
XEEa have charged, polar or bulky residues at this position (prekallikrein, Ser; 
Factor XI, Lys; Factor Xn, Met). Alternatively, disruption of an electrostatic 
network within the inhibitor loop might lead to a decrease in functional activity. 
Finally, Val is known to add stiffness to primary protein structure that may 
affect folding due to bifurcation near the backbone chain. Substitution with a 
small residue would lead to loss of this effect. This particular residue is at the 
approximate center of a flexible binding loop, the only area of the inhibitor that 
is not involved in a compact secondary/tertiary structure. 
We replaced this Val with Met, Gly, and Ser. We predicted a possible 
decrease in inhibitor activity due to introduction of steric hindrances which 
would disrupt tight inhibitor-enzsnne blading in mutants with the larger side 
chain (Met) or if important hydrophobic interactions have been lost (Gly). We 
predicted either a possible decrease in activity of the Val/Ser mutant due to a 
decrease in inhibitor stability through possible disruption a nearby network of 
electrostatic interactions, or an increase due to favorable interactions. 
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Proteinases and Serine Proteinase Activity 
Proteinases hydrolyze peptide bonds of proteins and are involved in many 
biological functions from general protein digestion to regulatory activities such 
as enzyme activation and transport of proteins across membranes (Neurath, 
1984). There are four major categories of proteinases, each member within those 
categories sharing a common functional characteristic: 
• serine proteinases, with a catalytically active Ser residue at their active 
center; 
• thiol proteinases, which share a free -SH group at the active site; 
• add (carboxyl) proteinases, maximally active under addic conditions; and 
• metal proteinases, requiring the presence of ions such as Ca^^ for enzyme 
stability and function. 
The metal and serine proteinases may share a common regulatory system, as 
suggested by increased expression of a metalloproteinase gene in response to 
loss of function of a serine proteinase gene (Ramesh and Kolattukudy, 1996). 
The serine proteinases are the most widely-studied and may be divided 
into six evolutionarHy-related dans. The chymotr3^sin dan contains ten 
families, all of which are endopeptidases (RawHngs and Barrett, 1994). Within 
the chsonotrypsin dan, the chymotrypsin family contains over 200 members and 
its members are most commonly isolated from animals, with few exceptions. In 
addition to their involvement in digestion, and the coagulation, fibrinolytic and 
complement pathways, they have other important functions and have also been 
implicated as pathogenic factors in several diseases (RawHngs and Barrett, 
1994). Studies in tumor cell lines have identified a putative serine proteinase as 
the mediator of mitogenesis on lymphocjrte surfaces (Packard et al., 1995) and 
blood coagulation Factor Xn has been shown to function as a mitogenic growth 
factor and to activate a signal transduction pathway which indudes a mitogen-
activated protein kinase (Gorden et al., 1996). Urokinase-t5^e plasminogen 
activator plays a role both in the process of cancer invasion and progression of 
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precancerous changes into cancer (Farinati et al., 1996). Infectious processes of 
the HTV and other viruses involve several serine proteases (Enocendo et al., 
1997; Decroly et al., 1996; Kido et al., 1996; Niwa et al., 1996; Decroly et al., 
1994; Hallenberg et al., 1993) and elastase has been shown to be involved in the 
pathology of lung disease (Cichy et al., 1997). Variations in levels of certain 
blood serine proteinases have been noted in models of metastasizing prostate 
cancers (Bhatti et al., 1996), and other blood factors have been associated with 
the formation of cataracts in the aging eye (Dotsenko et al., 1996). Apoptosis 
has been shown also to involve serine proteinases (Quan et al., 1996, Schlegel et 
al., 1995) and in mammals, acrosin is involved in the attachment to, and 
penetration of, the zona peUudda by spermatozoa (Barros et al., 1996). 
An essential Ser residue at the active site of a serine proteinase was 
demonstrated by Jansen et al. (1949). Later, a His residue at the active site was 
found to be important (Shaw et al., 1965). X-ray crystallographic studies 
revealed a common 'catalytic triad* at the active site in serine proteinases that 
involve Ser, His and Asp residues (Kraut, 1977). There are several proposed 
mechanisms for serine proteinase catalysis (Kraut, 1988), two of which are well-
defined: the electrostatic catalysis and double proton transfer (Warshel, 1987). 
The actual binding mechanism of the proteinase to either inhibitor or substrate 
appears to be similar (Laskowski and Kato, 1980; Bode and Huber, 1991). It 
involves formation of an acyl-enzyme intermediate and, after cleavage of the 
substrate/inhibitor (S/I) "reactive" bond and release of the carboxyl-terminal S/I 
fragment (acylation reaction) followed by a deacylation reaction Eind release of 
the amino-terminal S/I fragment. Four distinct enzyme regions are required for 
cataljrtic action (Bode and Huber, 1991): 
• oxyanion hole - the transition state intermediate is stabilized through 
hydrogen bonding between enzyme main chain hydrogen to the 
negatively-charged S/I carbonyl O of the residue at the amino end of the 
reactive bond; 
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• specificity pocket - a pocket into which the side chain of a reactive-site 
(S/I) residue must fit. This region confers a certain degree of specificity to 
the protease f3or a preferred side-chain. This pocket may be large or 
small, or very Shydrophobic or charged, any of which characteristics may 
result in a finer or more gross specificity; 
• P-sheet - an area of non-specific binding between enzyme and S/I. The 
non-specific binding of this area increases the stability of the transition 
state; and 
• catalytic triad - three residues (His, Ser, and Asp) which are invariably 
present. 
The side chain of the S/I residue at the amino side of the reactive bond 
must fit into the specificity pocket, although at least one instance of specificity 
being dependent on the two residues at the amino side of the reactive bond has 
been reported (Yamagata et al., 1995). The enzyme's catalytic basic His residue 
is thought to act as a proton acceptor firom the catalytic Ser residue hydroxyl 
group leading to the formation of a covalent transition state. Formation of the 
oxyanion intermediate is assumed to be the rate-limiting step for amide 
hydrolysis (Warshel et al., 1989). The exact role of Asp is stiU debated although 
it is generally thought that it stabilizes the positively-charged His of the 
transition state. Studies have shown, however, that it does play a role in the 
efficiency of catalysis (Craik et al., 1987) and the presence of an H-bond between 
His and Asp has been demonstrated (Halkides et al., 1996). The electrostatic 
catedysis mechanism assumes a sin^e proton transfer (firom Ser to His), while 
the double proton mechanism assumes that the transfer of proton from Ser to 
His is accompanied by a proton transfer fi:om His to Asp. The enzyme Ser Oy 
reacts with the carbonyl carbon of the residue at the amino end of the reactive 
bond, forming the acyl-enzyme intermediate, donating a proton to the active site 
His and releasing the carboxyl firagment of the S/I. It has been demonstrated in 
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subtilisin that the enzyme preferentially binds the tetrahedral intermediate 
adduct (O'ConneU and Malthouse, 1996). 
Subtilisin Novo in complex with Chymotrs^sin Inhibitor 2 (CI-2) is an 
example of a serine proteinase in complex with an inhibitor (McPhalen et al., 
1985b). A close-up (Figure 1) shows the reactive site bond between the inhibitor 
residues Met59 and Glu60 and the proteinase cataljiic triad (Ser221, His64, 
Asp32). The Ser221 hydroxyl O is within 2.5A of the Met59 carbonyl C. The 
Asp32 Oy2 is at 1.8A firom His64 H51, and the His64 Ne2 is 2.0A from the 
hydroxyl H of Ser221. A proton is transferred firom Ser221 to His64. The 
ionized Ser221 is positioned for a nucleophilic attack on the carbonyl carbon of 
Met59, resulting in a negatively-charged, or oxyanion, intermediate. His64 
donates a proton to the S/I amide N (carboxyl firagment) and the amino fragment 
is covalently bound to Ser221 to form the acyl-enzyme. 
Although the structure of Factor Xlla has not yet been determined, serine 
proteinases share a common catalj^c mechanism and are structurally similar. 
Figure 1. CI-2 in complex with subtilisin Novo. Enzjnne catalj^c 
triad (Ser221, His64, Asp32) and inhibitor reactive site residues 
(Met59, Glu60) are labeled. 
8 
Sequence similarities are seen near the active sites (Table 1). CMTI-V is an 
inhibitor not only of Factor Xn„ but of trypsin and chsnnotrypsin (weakly), aU of 
which are serine proteinsises. The structures of some of these have been 
determined, e.g., chsnnotrypsin (Figure 2, Tsukada and Blow, 1985) and trypsin 
(Figure 3, Read and James, 1988).-
Table 1. Sequence comparisons of Factor Xn, trypsin and kaUikrein 
ENZYME RESIDUES NEAR CATALYTICALLY-ACTIVE SERINE^ 
Factor XII CAGFLGGGTDACNGDSGGPLV 
Trypsin CAGYLEGGKDSCQGDSGGPW 
Kallikrein CAGYLPGGKDTCMGDSGGPLI 
RESIDUES NEAR CATALYTICALLY-ACTIVE HISTIDINE* 
Factor XII HS FCAGSLIAPCWVLTAAHCLNDRLN 
Trypsin YHFCGGS L INS QWWSAAHC YKSGIQ 
Kallikrein S FQCGGVLVNPKWVLTAAHCKNDNYE 
^Active site residues bolded 
Figure 2. Bovine a-chjonotrypsin 
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Figure 3. Trypsin from Streptomyces griseus 
Blood Coagulation and Factor XII 
A fibrin clot is an association of protein fibrin monomers which 
spontaneously assemble in a slightly-staggered side-to-side fashion. The 
monomers are elongate molecules approximately 46 nm in length and are 
products of the cleavage of fibrinogen. Certaui areas of fibrinogen are ridi in 
Asp, Glu, and in some cases, modified Tyr residues. These negatively-charged 
groups serve to prevent fibrinogen molecules from self-assembling. After 
cleavage of these charged fibrinopeptides the resulting fibrin monomers 
aggregate. The resultant clot is subject to lysis but is stabilized through 
covalent cross-linking between side chains. 
The formation of a fibrin clot is the final result of what has been described 
as an enzyme 'cascade' or 'waterfall' (MacFarlane, 1964; Davie and Ratnoff, 
1964). There are initially two pathways (intrinsic and extrinsic) which 
eventually unite to a final pathway. The intriasic pathway was demonstrated in 
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1863 by Joseph Lister who found that ox blood remained fluid while in an 
excised jugular vein but quickly clotted upon transfer to a glass container. 
Components already present in the blood (intrinsic) were activated on contact 
with an abnormal surface. Also, the addition of substances not normally present 
in the blood (extrinsic) can induce rapid clot formation. Each step of each 
pathway is catalyzed through the action of proteinase "factors". The precursors, 
or z3nnogens, of most of these enzymes circulate in the blood plasma. Table 2 
Hsts known factors involved in the intrinsic pathway (Tuddenham and Cooper, 
Table 2. Blood coagulation factors (intrinsic pathway) 
FACTOR FUNCTION 
I (Fibrinogen) Precursor to Fibrin 
la (Fibrin) Forms Clot 
rr (Prothrombin) Precursor to Thrombin 
Ila (Thrombin) Activates Factors V, XIII, VIII, 
Fibrinogen 
rV (Calcium) Cofactor 
V (Ptoaccelerin) Cofactor 
VI Activated form of Ptoaccelerin 
VIII (Antihemopl^a) Cofactor 
von WUlebrand Factor Involved in activation of VIII Cofactor 
IX (Christmas Factor) Activates Factor X 
X (Stuart Factor) Activates Prothrombin 
XI (Plasma thromboplastin antecedent) Activates Factor IX 
Kallikrein Activates Factor XII 
High Molecular Weight Kininogen Cofactor 
(HMWK) 
Xn (Hageman Factor) Initiates Intrinsic Pathway; activates 
Factor XI and Kallikrein 
XIII (Protransglutamidase) Stabilizes Fibrin Clot 
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1994). Thrombin is responsible for removal of approximately 3% of the 
fibrinogen parent protein in the form of NHg-terminal fibrinopeptides. 
Thrombin is also involved in various other coagulation pathway steps, for 
example, in activation of Factor Xnia which is involved in stabilization of the 
fibrin clot. Factor XUIa strengthens the clot through cross-linking, and possibly 
by making it less resistant to fibrinolysis (Lorand et al., 1980). Factor Xllla is a 
thiol proteinase; all other proteinases involved in the coagulation pathways are 
serine proteinases. 
Factor Xn, or Hageman factor, is believed to be involved in the initiation 
of the intrinsic pathway. Although there are no clinical S3miptoms in Factor XU 
deficiency, its absence does result in prolonged clotting time (Fujikawa and 
Davie, 1981) and it may be related to increased frequency of thrombosis 
(Lammle et al., 1991). Its lack of clinical ssnnptoms may be explained by the 
ability of thrombin to efficiently and independently of Factor Xn activate Factor 
XI (Gailani and Broze, 1993, Gailani and Broze, 1991, Naito and Fujikawa, 
1991). 
Factor Xn circulates in the blood at a concentration of between 29-
40//g/ml (Revak et al., 1974) and is a single chain 76-80 kD glycoprotein 
(Cochrane and Wuepper, 1971) which is hydrol3rzed and fragmented to its active 
form, Factor XHa (Kaplan and Austin, 1970; Kaplan and Austin, 1971). Factor 
xn is activated through an initial cleavage at the Arg353-Val354 peptide bond, 
resulting in a carboxyl-terminal light chain of molecular weight 28 kD 
containing a catalytic triad (Ser544, His383, Asp442). It is linked through a 
disulfide bond to an amino-terminal heavy chain of molecular weight 52 kD 
which contains the surface binding region (Revak and Cochrane, 1976). Further 
cleavages result in the production of P-Factor XEa (Dunn et al., 1982). P-Factor 
XEg is an active proteinase (Griffin and Cochrane, 1976) and has a molecular 
weight of 30 kD. It consists of a heavy chain of 28 kD containing the catal3^c 
region disulfide-linked to a carboxyl-terminal chain of either 10 or 19 amino 
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adds derived from the Factor Xn^ 52 kD heavy chain (Dimn and Kaplan, 1982). 
These two chains of P-Factor XTIa can be separated using SDS-PAGE (Revak et 
al., 1977). The heavy chain of Factor XOg (McMnllen and Fujikawa, 1985) and 
both chains of P-Factor XEEg (Fujikawa and McMullen, 1983) have been 
sequenced. The gene for Factor Xn is on chromosome 5 (Royle et al., 1988), is 12 
Eb in length and contains 13 introns and 14 exons (Cool and MacGillivray, 
1987). 
The predicted secondary structure, based on homology to related proteins, 
involves an N-terminal fibronectin-Uke type EE domain followed by an epidermal 
growth factor-like (EGF-like) domain, a fibronectin-lLke type I domain, a second 
EGF-hke domain, a kringle domain (possibly involved in binding of fibrinogen 
and fibrin), and the C-terminal serine proteinase catals^tic domain (Fujikawa 
and McMullen, 1983; McMuUen and Fujikawa, 1985). Comparison of the 
domain organization of Factor XU with domains of other haemostatic proteins 
reveal that Factor XII is more similar to tissue plasminogen activator and pro-
urokinase than it is to other factors, suggesting that Factor Xn may be more 
important to fibrinolysis and inflammatory response (Tuddenham and Cooper, 
1994). The presence of estrogen-responsive elements within the promoter and 
further upstream, in addition to the demonstrated enhancement of Factor XU 
concentration in plasma in response to estrogen levels, suggest that it is 
transcriptionally controlled by estrogen (CitareUa et al., 1996, Farsetti et al., 
1995, CitareUa et al., 1993). Additionally, a screening of Factor XEI-deficient 
patients revealed a point mutation (T-C) in one of these putative hormone-
responsive elements (Hofferbert et al., 1996). 
Factor XTI is activated through cleavage by kaUikrein or by self-cleavage 
upon contact with a negatively-boimd sxirface. Efficiency of activation can vary 
between species, possibly due to variation in eunino add sequences at regions 
surrounding the sdssile bond(s) (Yamamoto et al., 1996). Additionally, it's been 
shown that the binding of ligands to the kringle domain enhances activation by 
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Kallikrein cleavage (Ravon et al., 1995). It is also hydrolyzed in less efficient 
reactions by plasmin, Factor XI^ and tiypsin (Kaplan and Austen, 1971; 
Cochrane et al., 1973; Burrowes et al., 1975; Griffin, 1978). Regardless of the 
activator, surface-bound Factor XII is more readily activated (Griffin, 1978), and 
autoactivation is thought to be due to a conformational change in the protein 
that occurs upon contact (Rjkjaer and Schousboe, 1997). 
Two separate species were isolated from porcine plasma by ion-exchange 
column chromatography, each of which were estimated to be approximately 84 
kD and were not separable by SDS-Page. One species readily self-activated, 
while the second species was activated only in the presence of porcine plasma 
kallikrein, with an associated increase in efficiency upon addition of a 
negatively-charged surface (Mashiko et al, 1996). 
Various roles of Factor XII are shown in Figure 4. Prekallikrein and high 
molecular weight (HMW) kininogen also circulate as zjonogens in the plasma. 
Factor XEg converts prekallikrein to an activated form, kallikrein. Kallikrein 
can convert Factor XII to Factor XQa (Henriques et al., 1966). Factor XI 
circulates in the plasma in complex with HMW kininogen and upon conversion 
to Factor XI^ by Factor XH, is involved further in the clotting pathway (Kurachi 
et al., 1980). Factor Xn has been reported also to initiate the extrinsic pathway 
through activation of Factor VIE (Raddiffe, et al., 1977; SeUgsohn, et al., 1979) 
and is indirectly involved in the IHnin pathway through its interaction with 
prekallikrein, since kallikrein cleaves HMW kininogen to produce bradykinins. 
In the blood, Cl is the major inhibitor of Factor XII (Pixley et al., 1985). 
Proteinase Inhibitors and CMTI-V 
Proteinase inhibitors bind to proteinases, competitively inhibiting the 
bound proteinase. They are common in plants, animals and prokaryotes 
(Laskowski, Jr. and Eato, 1980). The nomenclature most often used to describe 
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Figure 4. Factor XII involvment in the fibrinolytic, coagulation, and 
bradykinin pathways (Tuddenham £ind Cooper, 1994) 
inhibitors and their targets is from Schecter and Berger (1967) and is shown in 
Table 3. Each inhibitor residue reacts with enzyme residues the matching 
enzyme subsite (i.e., the inhibitor PI residue interacts with those enzyme 
residues at Sl). The inhibitor reactive site peptide bond lies between PI and 
PI'. 
Most identified inhibitors target serine proteinases and at least 16 
families of serine proteinase inhibitors have been defined (Bode and Huber, 
1992). Assignment to the families is based on binding mechanism, topological 
similarity, and sequence homology (Laskowski, Jr., and Kato, 1980). The Potato 
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Table 3. Inhibitor/target enzyme nomenclature 
PROTEASE 
N-TERMINUS S3 - S2 - S1 - S1' - S2' - S3' C-TERMINUS 
N-TEBMINUS P3 - P2 - PI - PI' - P2' - P3' C-TERMINUS 
INHIBITOR 
I family is the only family with inhibitors in both animals and plants (e.g., leech, 
barley, beans, potato, pumpkin and tomato) with sequence identity ranging from 
35% to 74% when compared to the tomato leaf inhibitor I (Ryan, 1988). Because 
of the mjrriad functions of serine proteinases, inhibitors of these enzsrmes are 
important. An inhibitor found in human saliva has been shown to play a role in 
blocking viral transmission in HTV (Wahl et al., 1997, Shine et al., 1997, 
McNeely et aL, 1995). Kallikrein inhibitors have been used therapeutically in 
the treatment of infectious diseases such as septicemia and in tumor pathology 
(Maeda et al., 1996). A trypsin-chymotrypsin inhibitor isolated &om amaranth 
seed has been suggested to have an anticarcinogenic effect on certain breast 
cancers (Tamir et al., 1996) and the gene for another inhibitor, Msispin, which 
has an anti-tumor role in the mammary ^ands, was shown to have reduced 
expression in malignancy and no expression in metastatic cells (Zhang et al., 
1997). 
The largest group of serine proteinase inhibitors react in a common, 
substrate-like "standard mechanism" and are referred to as the "'small serine 
proteinase inhibitors" (Laskowski, Jr. and Kato, 1980). They are small proteins 
or protein domains of between 29 and 180 amino add residues. This type of 
inhibitor may vary in tertiary structure &om one family to another but all have 
a relatively compact hydrophobic core often interconnected by disulfide bonds. 
They also have a scaffold-supported exposed binding loop of a characteristic 
16 
nature. Stabilization of the loop also results from interactions between the 
inhibitor core and residues flanking the reactive site. Often a P2 or P3 residue 
is a cysteine which is disulfLde-connected with the hydrophobic core. In other 
inhibitors of this group (e.g.. Potato 1 and large Kunitz inhibitors) the loop is 
stabilized by an extensive hydrogen bond network between the inhibitor core 
and the binding loop (Bode and Huber, 1991). The PI residue of the inhibitor is 
involved in the proteinase specificity, e.g., tiypsin-hke enzyme inhibitors have 
either Lys or Arg at this site (Laskowski and Eato, 1980) and chymotrypsin-like 
enzyme inhibitors have either Phe or Leu at the site (Laskowski et al., 1983). 
The side chain of this PI residue fits into the target enzyme's "specificity 
pocket", or Si subsite. 
Laskowski and Kato's (1980) proposed standard mechanism of inhibition 
in which the proteinase inhibitor serves as a substrate to the proteinase 
suggests the inhibitor is turned over at an extremely slow rate due to its tight 
binding with the proteinase. Most inhibitors of serine proteinases bind the 
active site region of the target proteinase within the inhibitor surface reactive 
site. A cleavage of the reactive site peptide bond to yield a modified inhibitor 
then follows. 
Serpins (serine proteinase inhibitors) are a second group of inhibitors, 
and are large homologous (glyco)proteins. Most are specific inhibitors of serine 
proteinases, although a few are not inhibitors at aU but may have other 
functions. 
Hirudin, a selective inhibitor of thrombin, is an example of a third type of 
inhibitor. It is partially a compact globular protein, but has both an amino-end 
and carboxyl-end flexible stretch of residues. The carboxyl-end tail is composed 
of 18 residues and contains several acidic side chains which aid in the binding of 
thrombin (Bode and Huber, 1991). 
Plant proteinase inhibitors have been classified into six families by 
Laskowski and Kato (1980): 
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• Kunitz Soybean Trypsin Inhibitor Family 
• Bowman-Kirk Soybean Proteinase Inhibitor Family 
• Potato I Family 
• Potato n Family 
• Barley Trypsin Inhibitor Family 
• Squash Tr3^sin Inhibitor Family 
Plant inhibitors are usually at their highest levels in seeds and tubers but 
are found also in roots and leaves. They are thought to be involved in regulation 
and in defense against pests (Ryan, 1989). Several inhibitors have been isolated 
from legumes and their chemical and inhibitory properties are the bases of die 
Kunitz and Bowman-Birk inhibitor families. Trypsin inhibitors &om plants 
generally fall into one of these families. The proteinases inhibited by plant 
inhibitors are usually found in animals, bacteria, and fungL 
Inhibitor I and Inhibitor n proteins were identified in potato and tomato 
as responses to woimding (Green and Ryan, 1972; Ryan, 1978; and Plunkett et 
al., 1982). Several of these genes have been isolated from both potato and 
tomato. The inhibitor I protein is 69 amino adds in length in tomato and 71 in 
potato with the variation due to differing processing sites. -The inhibitor n 
protein is 123 amino adds long in both ^edes, and apparently is a result of a 
gene duplication event, having two inhibitor reactive sites (Graham et aL, 1985, 
Cleveland et al., 1987). 
Three trypsin inhibitors from Momordica charantia (MCI-1, MCI-2, MCI-
3) have been isolated (Zeng et al., 1988) and range ia size from 62 to 77 amino 
adds, with 0 to 7 disulfide bridges. MCI-3 has no cysteine residues and is 
homologous to members of the Potato I inhibitor family. Three isoinhibitors of 
trypsin were also isolated from Ecballium elaterium. One of these, EETI n, was 
found to be homologous with members of the squash fsunily (Favel et aL, 1989). 
Several inhibitors of Factor XH^ have been isolated from plant tissues. 
Inhibitors from pumpkin (Cucurbita maxima) seeds (CMTI-I, CMTI-in, CMTI-
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IV, and CMTI-V) have been puiified and sequenced (Wieczorek et al., 1985, 
Polanowski et al., 1988, Enshnamoorthi et al., 1990). CMTI-I, CMTI-III, and 
CMTI-IV, ranging in size from 29 to 32 amino adds, are t±te smallest known 
plant inhibitors of taypsin and Factor XH, and are members of the Squash 
family of inhibitors, while CMTI-V is a member of the Potato I family. 
CMTI-I, isolated by Hojima et al. (1982) was shown to strongly and 
specifically inhibit P-Factor Xlla and trypsin. It has 29 amino adds induding an 
amino-terminal arginine residue, a carbosgrl-terminal glycine residue, three 
cystines, and a reactive site arginine residue. CMTI-III was isolated as a 
trs^pain inhibitor (Polanowski et al., 1980) and as an inhibitor of P-Factor Xn, 
(Hojima et aL, 1982). It consists of 29 amino add residues and 3 disulfide 
bridges with a reactive site peptide bond ArgS-IleG. CMTI-IV was isolated in 
1983 (Leluk et al., 1983) and described in more detail by Weiczorek et al. (1985). 
It contains 32 amino adds. 
et al., 1990). It is a seven kD protein strongly specific for P-Factor XTTa. It 
consists of 68 amino adds in a sin^e chain with one disvilfide bridge (all other 
CMTIs have three disulfide bridges) and has a trypsin-senintive bond at the 
reactive site (Lys44-Asp45). Other Potato I family members are &om plants 
(e.g., barley, potato, tomato, bean, momordica) and one from animal (leech), none 
of which is a specific inhibitor of P-Factor XHg. The Potato I family is distinct in 
not being functionally dependent on disulfide bridges (Svendsen et al., 1982). 
Although at least one other member of the Potato I family has two cysteine 
residues, CMTI-V is the first member of the Potato I inhibitor family whose 
determined structure indudes a disulfide bridge. 
Dissodation constants of CMTI-V in complex with trypsin and P-Factor 
Xn, have been measured at 1.6 x 10"® and 4.1 x 10"® M, respectively 
(Krishnamoorthi et al., 1990). It does not inhibit kaUikrein, unlike most other 
plant inhibitors of P-Factor Xlla (Hojima et al., 1982; Chong and Reeck, 1987). 
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In fact, low molecular weight substrates for P-Factor Xlla have been shown to be 
even better substrates for kallikrein (Hojima et al., 1980; McRae et al., 1981). 
Wen et al. (1993) designed a chemically-synthesized DNA based on the amino 
add sequence of CMTI-V, and expressed it as a fusion protein (Table 4). 
Table 4. Nucleotide and amino acid sequence of Clone 70-1 
-24 ATGGCTAGAATTCGCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCA 24 
- 7  A R I R A R G S S C P G K S S  8  
TGGCCACACCTGGTAGGTGTTGGTGGTTCCGTTGCTAAGGCTATCATC 72 
W P H L V G V G G S V A K A I I  2 4  
GAAAGGCAGAATCCGAACGTTAAAGCTGTTATCCTGGAAGAAGGTACA 120 
E R Q N P N V K A V I L E E G T  4 0  
CCGGTTACCAAGGACTTCAGGTGCAACAGGGTTAGGATCTGGGTTAAC 168 
P V T K D F R C N R V R I W V N  5 6  
AAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGTTAACGCGGATCC 216 
K R G L V V S P P R I G  6 8  
Mutation of CMTI-V and subsequent measurement of inhibitory action 
may provide further insight into mechanisms of inhibitor-proteinase binding, 
especially with regards to their specificity and strength. Additionally, mutation 
studies can provide insight into determinants of enzyme or inhibitor stability 
and function. Such information may be valuable in the development of new 
drugs for use in treatment of cardiovascular disease and mjndad other diseases 
in which serine proteinases are being foimd to be involved. 
The spedfidty of inhibitors for target proteinases has been studied using 
this approach. McWherter et al. (1989) substituted residues at the PI site of 
CMTI-in, and foimd it to have altered specificity for human leukocyte elastase, 
a proteinase involved in acute and chronic lung injiiry, as weU as human 
leukocyte cathepsin G, which has been shown to degrade senun and connective 
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tissue proteins. An alteration of specificity of CI-2 through replacement of the 
Pi residue was demonstrated by Longstaff et aL (1990) and Heinz et al. (1992) 
also altered the specificity of Eglin c through substitutions at PI. Similar results 
were found with the leech inhibitor antistasin by Hoffman et al. (1992). Protein 
stability studies have also lended themselves well to this methodology. 
Matthews et al. (1993) showed decreased stability of CI-2 mutants ne39Val, 
ne39Leu, and Arg67Ala (P8'). Jandu et al. (1990) also showed destabilization of 
CI-2 through substitution of an Ala residue for the PS'Arg residue. Jackson et 
al. (1993) studied hydrophobic contributions to the stability of the main core in 
^-2, while Otzen et al. (1995) and Jackson and Fersht (1994) looked at stability 
of the reactive site loop. 
Mutant forms of CMTI-V have been studied (Wen, 1993; Wen, 1995), 
focusing on the PI, P2, P3', P6', and P8' positions, EUid removal of the disulfide 
bridge. The wild-type P2 is Thr, which is involved in hydrogen bonding 
interactions with other loop residues. Replacement with Ala involved loss of -
hydrogen bonding potential and resulted in decreased activity toward P-Factor 
Xllg and trs^psin. Replacement with Ser and Asn resulted in decreased activity 
toward P-Factor XEE,, but not toward trypsin. Changes in the Pi position 
showed lowered activity levds toward P-Factor XHa and tr3i)sin, and increased 
activity toward chymotrjnpsin 0L^ys44Leu) or an increase toward P-Factor XUg 
and no change toward trypsin and chjmiotrypsin (Lys44Arg). Arg residues at 
P3', P6', and PS' are thought to be important stabilizers of the inhibitor loop in 
relation to the core; replacement of these with residues imable to form side-
chain hydrogen bonds resulted in instances of lowered activity toward P-Factor 
Xlla only (Arg47Ala, ArgSOLys, Arg50Gln, Arg52Ala, Arg52Lys, and Arg52Gln); 
both tr3T)sin and P-Factor XOg (Arg50Ala); and no change toward either 
(Arg47Gln, Arg52Lys). Removal of the disulfide bond (Cys3Ser/Cys48Ser) 
resulted in no detectable change in inhibitor activity. 
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Structure of CMTI-V and Other Potato I Inhibitors 
The solution structures of CMIl-V have been determined by 2D ^H-NMR 
and associated distance geometry/structure refinements (Cai et aL, 1995a). The 
refined average structure is shown in Figure 5. This structure is siTnilar to 
structures of other members of the Potato I family, e.g., Eglin c (Figure 6) fi:om 
the leech Hirudo medicinalis (Bode et al., 1986) and (Figure 7) barley's 
Chymotrypsin Inhibitor 2 (CI-2) (McPhalen and James, 1987). Similarities in 
structure are demonstrated in Figures 8 and 9 in which we selected 21 
sequential C" atoms (P11-F9') firom each molecule and superposed them using 
the RMS Fit Program (Hyperchem, Canada). These superpositions resulted in 
root mean square (r.m.s.) deviation values of 2.20A (Eglin c) and 2.44A (CI-2) 
fi:om tJie average solution structure of CMTI-V. The primary structure of CMTI-
V related to its secondary structure is listed in Table 5. 
Figure 5. Sfaructure of CMTI-V. 
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Figure 6. CI-2 firom barley, Hordeum vulgaris 
Figure 7. EgHn c from leech Hirudo medicinalis 
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Figure 8. CMIT-V (arrow) and CI-2 overlayed through selection of 21 
a-carbons. RMS=2.44A. 
Figure 9. CMTI-V (arrow) and Eglin c overlayed through 
selection of 21 a-carbons. RMS=2.20A. 
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Table 5. Primary and secondary structure relationships in CMTI-V® 
RESroUES SEQUENCE SECONDARY ELEMENT 
3,48 C,C Disulfide bridge 
7-9 ssw P-sheet (antiparaUel to 67-65) 
12-15 LVGV Type n turn 
18-28 SVAKAHERQN a-helix 
28-31 NPNV Type I turn 
32-38 KAVELEE P-sheet OparaUel to 51-56) 
41-48 PVTKDFRC Binding loop 
47-50 RCNR Type I turn 
51-56 VRIWVN P-sheet (parallel to 32-38) 
57-60 KRGL Type m turn 
62-60 WL P-sheet (antiparaUel to 54-56) 
67-65 mp P-sheet (antiparaUel to 7-9) 
"Table based on information from Cai et al., 1995a 
Cai et al. (1995a) fotmd Trp9 had nudear Overhauser effects (NOEs) on 
the entire inhibitor core, with espedally strong effects on Val5I, Pro65, Arg66, 
ne67 (all within P-sheet structures) and ne24, Gln27 and Asn28 (within the a-
heUx), suggesting its importance to overall protein stability. Lys6, Lys21, 
Arg50, and Arg52 were rigid in solution. They also found probable hydrogen 
bonds between Lys6-Gln27, Lys21-Ala33, Arg50-Asp45, Arg52-Thr43, and 
Glu25-Ala33. While the binding loop of CMTI-V is not as compactly folded as is 
its core, ten residues that are either part of the loop or have side chains 
protruding into the loop are hydrophobic. Sequence comparisons between 
CMTI-V, Eglin c and CI-2 show full conservation of hydrophobic residues at PIO, 
P3, P2', P7', P9', PIO, and high levels of conservation at P9 and PIl'. 
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Table 6 lists several members of the Potato I inhibitor family and their 
sequences between Pll and Pll'. Several individual residues are 
fully conserved: Thr at P2, Arg at P6', Val at P7', and (with only one exception) 
Arg at P8' and (with only two exceptions) Val at P3. A Ser or Thr is conserved at 
P5 and a negatively-charged residue is conserved at PI'. Bolded positions 
(headers) are those inhibitor positions found by McPhalen and James (1988) to 
have interactions with enzyme residues in complexes of Eglin c and CI-2 with 
subtilisin. 
Table 6. Sequence comparisons of Potato I family inhibitors 
AMINO ACID SEQUENCE 
11 10 9 8 7 6 5 4 3 2 1 1' 2' 3' 4' 5' 6' 7' 8' 9'10' 11' 
OCTI-V V r L E E G T P V T K D F R C N R V R I W V 
EGLIN C Y F L D E G S P V T L D L R Y N R V R V F Y 
CI-2 I V L P V G T I V T M E Y R I D R V R L F V 
BEANb Q V V P Q D S F V T A D Y K F Q R V R L Y V 
POTATOc H I L L N G S P V T L D I R C D R V R L F D 
TCMATOd P I L L N G s P V T K D F R C D R V R L F D 
BEANe Q V S P H D s F V T A D Y N P K R V R L Y V 
AMARANTHf I V K H E R s G F T K D F R C D R V W V V V 
TCMATOg P I L L S G s P I T L D Y L c D R V R L F D 
'Bolded positions are those shown to have direct contact with target enzymes. 
^Vicia faba, Swiss Prot. P08820, Svendsen et al. , 1982. 
'Solanum tuberostmir Swiss Prot Q00783, Lee and Park, 1989. 
"Lycopersicon peruvianam, Wingate et al. , 1989. 
'Phaseolus angularis, Nozawa et al., 1989. 
'Aimranthus caudatus, Beugaard et al., 1994. 
''Lycopersicon esculentum, Graham et al. , 1985. 
After hydrolysis of their reactive site bond most inhibitors are held 
together through disulfide bridges. However, most members of the Potato I 
family do not have disidfi.de bridges and their stabihty after cleavage is thought 
to be due to extensive hydrogen bonding and electrostatic interactions within the 
core and between the loop and core (Bode and Huber, 1991). Crystal studies of 
Eglin c (which lacks disulfide bridges) hydrol3rzed, but not bound, by subtilisin 
showed seven residues (at the carboxyl side of the reactive bond) of the binding 
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loop were in a completely different conformation tiian that of unhydrolyzed 
inhibitor. The remaining inhibitor residues were in an essentially-unchanged 
conformation (Betzel et al., 1993). They suggested this to be reflective of overall 
inhibitor stability whether or not a disulfide bridge is present. CMTI-V does 
have a disulfide bridge between a loop Cys (P4') and the carboxyl-terminal Cys 
but studies of hydrolyzed inhibitor show a reduction in both binding affinity and 
inhibitory activity toward trypsin and P-Factor Xlla (Cai et al., 1995b). 
Serine Proteinase/Inhibitor Complex and Mutant Selection 
Site-spedfic mutations were made in the internal sequences of Clone 70-1, 
which is a fusion protein based in tJie wildtj^pe's amino add sequence (Wen, 
1993), hereafter referred to as wildtype. The mutant genes were expressed and 
activity of their mutant protein products were compared with wild-type CMTI-V 
activity. Two approaches were used in mutant selection with the ultimate aim 
of the substitution of one amino acid readue: 
• mutations which resulted in amino add substitutions at the reactive site 
of the CMTI-V gene, which might supply information about the individual 
importance of reactive-site residues; and 
• mutations which resulted in amino add substitutions at other sites along 
the length of the CMH-V protein, which might supply information about 
the effects of such replacements on tertiary structiure £md/or fimction. 
Although the reactive loop of proteinase inhibitors is the most important 
region of direct contact with the proteinase, individual amino adds 
distant in primary sequence may be dosely assodated with the 
maintenance of three-dimensional structure and/or activity (Jackson and 
Fersht, 1993). 
Inhibitor binding to enzyme has been shown to be similar to that of 
substrate binding (Laskowski and Kato, 1980). While the substrate is rapidly 
hydrolj^ed and released, however, inhibitor binding is tight and release is slow. 
Cleavage may or may not occur but while in complex the reactive bond remains 
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intact (Bode and Huber, 1991). Hydrolyzed CMTI-V retains some inhibitory 
activity toward trypsin and P-Factor Xlla, although the binding affinities are 
greatly reduced due to the increased flexibihty of the binding loop (Cai et al., 
1995b). 
McPhalen and James (1988) compared the structures of Eglin c in 
complex with subtilisin Carlsberg and CI-2 in complex with subtilisin Novo and 
found that inhibitor-enzyme contacts were limited almost exclusively to contacts 
between enzjnne residues and inhibitor binding loop residues. Twelve loop 
residues in Eglin c made 134 contacts (< 4.0A) with 25 enzjone residues, and 9 
CI-2 loop residues made 139 contacts with 21 enzsnne residues. Bode and Huber 
(1991) described the interactions of the binding loop residues with the enzyme 
active site. The Pl-Pl' bond is the reactive bond. N-terminal to this bond, 
residues (usually P4-P2) form a P-sheet with enzyme residues through main 
chain hydrogen bonds. Residue PI is an important factor in determining the 
spedfidty of an inhibitor for a target enzyme; its side chain fits into the 
enzyme's "specificity pocket". The carbonyl C of PI is in close contact (usually 
approximately 2.7A) with the active site's Ser Oy and the reactive bond is intact. 
Between P9 and P4' several exposed side chains interact with the enzyme, 
usually hydrophobically. The enzyme subsites involved in these contacts consist 
usually of between 15 and 25 residues. Residues P2'-P4' are involved in loose 
binding to the enzyme which is not highly specific and may not be important to 
the tightness of binding, but whose side chains may prevent binding to certain 
enzymes through steric hinderance. 
One important question is why an inhibitor is not a substrate, since it 
apparently binds in the manner of a substrate. The tertiary structures of the 
small serine proteinase inhibitors are qtiite similar in spite of their primary 
sequence variations. The binding loop is held rigid against the compactly-folded 
core. It has been suggested that the rigidity of the inhibitor while in complex 
with the enzyme, in contrast to the more flexible substrate, may result in tighter 
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binding and slower release. In most serine proteinase inhibitors the P2 or P3 
position is occupied by a Cys residue whose disulfide bridge with a core residue 
is thought to have an important stabilizing efifect on the inhibitor-enzjnne 
complex (Bode and Huber, 1991), In the Potato I family the binding-loop Cys is 
absent and the P3 position has a fiJly conserved hydrophobic residue. 
Stabilization of the rigid inhibitor-enzyme complex is believed to be a result of 
extensive electrostatic and hydrogen-bonding interactions between binding loop 
and core residues (Laskowski and Eato, 1980). They further suggested that the 
equilibrium between the intact-inhibitor/enz3nme complex and the acyl-enzjmie 
intermediate Hes strongly toward the intact inhibitor. Cleavage of the inhibitor 
results in a fiee amine group which retains its position, allowing re-formation of 
the inhibitor reactive peptide bond. LongstafiT et al. (1990) described such a 
transient acyI-enz3nne-amiQe complex (E-C0R*NH2R') during which the amine 
group is held rigid: 
E + RC0NHR'«=>E*RC0NHR'-E-C0R*NH2R'-E-C0R + NHaR'-E + RCO," + H" 
This would introduce an additional equiUbrium constant between E-RCONHR' 
and E-C0R*NH2R' with the equilibrium favoring the unhydrolyzed inhibitor. 
Kinetic studies of a double mutant of Egiin c (LeuPlArg-AspPl'Ser; Pl-
Pl') showed it to be a substrate rather than an inhibitor (Heinz et al., 1992). 
Subsequent NMR study of this mutant suggested the loss or weakening of the 
internally-stabilizing PI' hydrogen bond between the Asp (PI*) side chain and its 
backbone amide proton. They did construct and test the single LeuPlArg 
mut£uit (which resulted in an enzyme spedfidty change as expected) but did not 
report construction of the sin^e PI' (Asp46Ser) mutant. 
Comparisons of CMTI-V, Eglin c and CI-2 binding loop sequences find 
them to be similar. The PI' position is occupied by Asp in both CMTI-V and 
Eglin c; it is replaced by Glu in CI-2. A charged PI' residue is fuUy conserved 
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among the Potato I family of serine proteinase inhibitors (Laskowski and Kato, 
1980). Also, 99 of 100 avian ovomucoid serine proteinase inhibitors (not 
members of the Potato I family) have either a PI' Asp or Glu (Laskowski et al., 
1983). McPhalen and James (1988) found after superposing the flexible loops of 
CI-2 and Eglin c that Eglin c's Asp60 (PI*) Oy2 and CI-2*s Glu60 (PI*) 082 were 
only O.eA apart in spite of the shorter Asp side chain. They measured a shift in 
several Eghn c side chains (Arg62, Arg65, Arg67, Gly70) toward the shorter Asp 
side chain. These side chains are involved in electrostatic and hydrogen bonding 
interactions with PI' Asp and other loop residues. 
The structures of Eglin c and CI-2 both in complex with their target 
enzjones and in their non-complexed forms have been reported (Hyberts et al., 
1992, Hipler et al., 1992; McPhalen and James, 1988; McPhalen and James, 
1987; Bode et al., 1986). Therefore, comparisons may be made between inhibitor 
conformation complexed and non-complexed. Side chain conformational 
alterations occur within the binding loop. 
Figure 10. CI-2, non-complexed, arrow indicates PI' 
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Figure 11. Eglin c non-complexed, arrow indicates Pr 
r 
Figure 12. CI-2 complexed, arrow indicates PI' 
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Figure 10 is CI-2 non-complexed and Figure 11 is EgHn c non-complexed. 
These can be compared with CI-2 (Figure 12) and Eglin c (Figure 13) in complex 
with subtiHsin (inhibitors only shown). In both cases the PI' side chains have 
rotated inward toward the body of the inhibitor, either initiating or increasing 
hydrogen bonding and electrostatic interactions between the PI' residues and 
side chains that protrude from core Arg residues into the binding loop. Table 7 
Usts differing conformational angles between complexed and non-complexed 
inhibitors. The PI' residue is involved in extensive H-bond networking with the 
inhibitor core and so may be an important stabiLizdng factor in increase of the 
tightness of binding between the inhibitor and enzyme (Bode and Huber, 1991). 
In light of suggestions by LaskowskL and Kato (1980) and Heinz et al. (1992) of 
possible serine proteinase mechanisms, discussed earher, it is possible that a 
potentially-stabilizing role of the Pi' residue may be a factor in allowing the 
newly-formed amine group of the carboxyl fragment to be positioned for a 
nucleophihc attack on the acyl-enz3nne intermediate. 
Figure 13. Eglin C in complex, arrow indicates PI' 
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Table 7. Comparison of PI and PI' conformational angles in complexed and non-
complexed Inhibitors (degrees) 
Pi pr 
Phi Psi Phi Psi 
EgUn c 
Non-complexed" •81.0 12.0 -99.0 159.0 
Complexed' -115.0 45.0 -97.0 169.0 
CI-2 
Non-complexed'" •63.0 27.0 -91.0 128.0 
Complexed'" -103.0 34.0 -91.0 146.0 
'Hipler et al., 1992 
''McPhalen and James, 1987 
Figure 14 shows non-complexed CMTI-V and its Asp PI' side chain. 
Earlier modeling (Cai et al., 1995a) showed no prohibitive contacts occurring as 
a result of rotation of the Asp side chain inward to a position similar to that of 
the Pi' residues of complexed Eglin c and CI-2. We are interested in the Pi' 
residue as a possible stabilizing factor in the CMTI-V/enzyme complex. We have 
selected Val, Leu, Asn and Glu as replacements for Asp (PI'). The Val and Leu 
substitutions may prevent formation of potentially-stabilizing side chain 
hydrogen bonds and electrostatic interactions. We hypothesized that binding 
between enzyme and mutant inhibitors will occur normally but that loss of 
stabilizing interactions may result in looser binding and thus a decrease in, 
orabsence of, mutant inhibitor activity. Asn has potential H-bonding 
capabilities that may contribute partly to replacement of the lost electrostatic 
interactions. We predicted a lowered, but not loss of, function. Glu, with its 
reactive C00~ group should be able to form the same interactions and although 
we expected to see no decrease, an observed decrease might be due to its longer 
side chain. 
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Figure 14. Stereoview of CMTI-V PI', arrow indicates Asp Pi' 
We are also interested in the full conservation of a hydrophobic residue at 
the P3 position in the Potato I family of serine proteinase inhibitors (Laskowski 
and Kato, 1980; Table 6). The P3 side chain has been shown thus far to have no 
specific enzjnme binding site but to be involved in inhibitor interior hydrophobic 
interactions (McPhalen and James, 1988). Its side chain is in close contact with 
hydrophobic side chains (in CMTI-V, e.g., V£d-Trp54, a minimum of 2.5A; Val-
Phe46, a minimum of 2.3A; see Figure 15). In both CI-2/enzyme and Eglin 
d&axyme complexes with subtilisn the P3 Val side chain faces inward (Figures 
16 and 17). Figure 18 is a closeup of the subtilisin/CI-2 complex; all enzsnne and 
inhibitor residues involved in intermolecular contacts are shown (McPhalen et 
al., 1985b). 
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Figure 15. Stereoview of CI-2 in complex. P3 Val is indicated 
by arrow. 
Plie46N 
Figure 16. CMTI-V with contacts between Val42, Try54 and Phe46 shown in color. 
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/ 
Figure 17. Stereoview of Eglin c in complex. PS Val is 
indicated by arrow. 
Figure 18. Stereoview of CI-2 (red) in complex with subtilisin (black); all 
residues with known interactions are shown. 
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We chose to substitute CMTI-Vs P3 residue with Met, Gly and Ser. 
Figure 19 illustrates the position of the P3 Val within CMTI-V. We have used 
preliminary modeling techniques to predict the effect of possible substitutions. 
Figure 20 is a modeled replacement of Val by Gly, and shows that this should 
not be volumetrically inhibited. The Gly substitution may have a destabilizing 
affect due to loss of interior hydrophobic affects, resulting in a decrease in 
activity. In Figure 21 Met has been substituted for Val and it can be seen that 
very dose contacts witli side chains interior to the loop would probably prevent 
an intemaUy-packed conformation. Rotation of the side chain results in 
minimum contact distances (ranging firom 0.6A to 1.6A), less than the sum of the 
van der Waals* radii. A decrease of inhibitory activity in Val42Met might 
suggest that an outward-turned Met side chain may introduce steric hindrance 
within the inhibitor/enzyme complex. 
Val42Ser is also being created to study the effect of a potential H-bond 
donor residue at the P3 position (Figure 22). Rotation of the side chain brings it 
within hydrogen bonding distance of atoms already involved in hydrogen bonds 
with other residues. If the side chain is forced to the interior of the inhibitor, its 
reactivity might potentially disrupt the normal hydrogen bond network, possibly 
residting in a decrease in activity. This would be an interesting comparison 
with the Val42Gly mutant relating possibly to the relative importance of the 
hydrophobic vs. hydrogen-bonding components. 
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Figure 19. Stereoview of CMTI-V with modeled substitution of Gly (arrow) for 
P3Val. 
Figure 20. CMTI-V with labeled PS Val and interactions 
with Phe46 and Trp54. 
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Figure 21. Stereoview of CMTI-V with, modeled substitution of Ser 
(arrow) for P3 Val. 
Figure 22. Stereoview of CMTE-V with modeled substitution of Met (arrow) for P3 
Val. 
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PARTI. ANALYSIS OF PI* MUTANTS 
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INTRODUCTION 
The PI' residue in CMTI-V is aspartic add. The comparative primary 
sequences of the Potato I family show a few positions of full conservation; the PI' 
is one of those positions (see Table 6). AU members of the family have a 
negatively-charged amino acid at that position, and in aU cases except CI-2 with 
a ^utamic add, it is aspartic add. This level of conservation immediately 
makes the PI' side chain an interesting point of study. Additionally, the obvious 
fact that it is at the carboxyl-side of the reactive bond indicates that whether or 
not its side chain is of import to inhibitor function, its backbone amino group 
certainly is. 
Since the single exception in this family to the conservation of the 
aspartic add is a ^utamic add, it appears logical to suggest that the negative 
charge of the side chain is the target of the conservation. This presents two 
general approaches to mutagenesis studies: substitution of a positively-charged 
amino add, or substitution of a non-charged amino add. Our first two mutants 
selected were Asp45Leu and Asp45Val which we chose for the following reasons: 
• we hypothesized that intramolecular electrostatic and H-bonding 
interactions of the aspartyl side chain with loop/core residues are involved 
in inhibitor function. Replacing Asp with Leu and Val eliminates both of 
these types of interactions; and 
• valine is relatively similar in bulk and size to the aspartic add residue, 
reducing the chance of the additional of steric hindrances having to be 
taken into account (Figure 23). 
Additional mutants created were Asp45Glu and Asp45Asn, selected for 
the following: 
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Amino 
Acid 
Asp 
KU 
' / 
Residue 
Weight/ 
Van der Waals 
Volume 
115.09 
(91A^ 
Leu 113.16 (124A^ 
Va] 99.14 (lOSA^) 
Glu 129.12 (109A') 
Asn 114.11 
(96A^ 
Figure 23. Wildtype PI' Asp side chain and 
replacements. 
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• the negative charge lost by removal of the aspartic add is replaced by 
glutamic acid. The Glu side chain should be positioned to participate in 
the same interactions as those of Asp, with an additional affect of a larger 
side chain. We hypothesized that the Asp45Glu mutant would be as good, 
if not better, an inhibitor; and 
# we hypothesized that upon exposure to the highly charged network 
surrounding the PI' area, the amino and carbonyl group H-bonding 
capacities of the Asn side chain, also of similar weight and bulk to Asp, 
might be able to compensate somewhat for loss of the Asp side chain 
interactions. We expected to see inhibitory activity, though at a decreased 
rate. 
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METHODS 
Mutagenesis 
A PGR overlap extension method (Ho et al., 1989) was used to create site-
specific mutations in the internal regions of CMTI-V. Pairs of synthetic 
oligomers with overlapping regions containing internal CMTI-V sequences 
including the desired base substitutions were designed such that the following 
amino acid substitutions were introduced at position 45 (?V): Leu, Val, Asn, 
Glu. Mutagenic oligonucleotides were ordered &om Keystone Laboratories 
(Menlo Park, CA) (Table 8). The PGR overlap extension consisted of three steps 
(Figure 24). In the first (mutational) step PGR was used in two separate 
reactions per mutant each involving; a single mutagenic oligomer (either 
forward or reverse); a flanking primer; and a template (recombinant DNA 
isolated firom wild-tjTpe GMTI-V Clone 70-1). This clone was in the plasmid 
pGEX (pGEX70-l) in the E. coli host JM109. The flanking primer was either 5' 
Bam or 3' PTI (Wen et al., 1993). 
Table 8. Sequences of mutagenic ohgomers for PGR overlap extension method. 
For each set of mutants both forward (F) and reverse (R) primers are shown, 
with mutagenic codons indicated in bold. 
MUTANT MUTAGENIC OLIGOMER 
D45V/L(F) 5' -A-GGT-ACA-CCG-GTT-ACC-AAG- (C/G) TC-TTC-AGG-TG-3' 
D45V/L(R) 5* -T-AAC-CCT-GTT-GCA-CCT-GAA-<3A(C/G) -CTT-GGT-AA-3' 
D45E(F) 5' -GAA-GGT-ACA-CCG-GTT-ACC-AAG-SJVA-TTC-AGG-3 ' 
D45E(R) 5' -GTT-GCA-CCT-GAA-TTC-CTT-GGT-AAC-CGG-TGT-3' 
D45N(F) 5' -GAA-GGT-ACA-CCG-GTT-ACC-AAG-AAC-TTC-AGG-3' 
D45N(R) 5* -GTT-GCA-CCT-GAA-GTT-CTT-GGT-AAC-CGG-TGT-3 ' 
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GENERATION OF TWO OVERLAPPING MUTANT FRAGMENTS: 
rm 
roRWARP tnnvuawic oug^:^ 
EXTENSION OF ANNEALED OVERLAPPED FRAGMENTS: 
ISOLATION OF FULL^IZED MUTANT INSERT: 
BAM HI 
• 
BAM HI 
Figure 24. Polymerase chain reaction overlap extension mutagenesis method 
(JB-oetaL, 1989) 
The full-length DNA was recovered and digested with Bam HI. The insert 
was gel purified and Ugated to the BamHl site of pT7-7 with T4 DNA Hgase 
(New England Biolab). The recombinant vector was transformed into E. coli 
strain JM109. Single colonies were transferred to a gridded plate with media 
containing 100 fxg/vol ampidllin, and recombinant colonies were selected using 
colony/plaque screen membranes (DuPont) and labeled 70-1 insert (Multiprime 
DNA Labelling System, Amersham). Plasmids from positive colonies were 
sequenced using the Sequenase Quick-Denature Plasmid Sequencing Kit 
(United States Biochemical). Sequencing resiilts were analyzed using the 
sequence analysis software "Seqaid" (Rhoads and Roufa, 1989). Complete 
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sequencing of each strand was done to verify that the mutated sequence was 
present in the proper orientation and with the correct sequence. 
Expression of Mutant Genes 
The mutant sequences were subcloned into the BamHI site within the 
multiple-doning site of the expression vector pT7-7, which contains the T7 
promoter and is dependent on T7 RNA polymerase for target gene expression. 
The recombinant vector was transformed into the E. coli host BL21(DE3), with 
the T7 RNA polymerase gene under control of the lacZ promoter (Studier et al., 
1990). The promoter is inducible through the addition of isopropyl-l-thio-P-D-
galactoside CDPTG). Cells &om one colony containing the recombinant DNA were 
transferred and cultivated overnight in LB broth with 200 //g/ml ampidUin. The 
cell culture was diluted 1:10 and then placed once again at 37° C at 200 rpm 
until an O.D.600 of 0.6-0.7 was reached. 
IPTG (1.5 mM) was added to the culture and the cultures remained on a 
shaker for an additional four hours. CeUs were harvested by centrifiigation at 
4000xg for ten minutes at 4°C. A sonication/cooling cycle was used followed by 
centrifiigation at 4°C for 30 minutes at 16000xg to obtain cell-free extract. 
Over-expression of the proteins was verified by SDS-PAGE, and a CMTI-V 
antibody affinity coliunn was used to isolate the recombinant proteins. Protein 
purity was checked using SDS-PAGE and Coomassie briUiant blue stain. 
Inhibition Assays 
The mutant and wild-type inhibitors were tested against bovine trj^psin 
(Sigma) and human P-Factor XII3 (Calbiochem). Residual activity of a given 
proteinase was measured after incubation with inhibitor (Wen et al., 1993). 
Various amounts of inhibitor were mixed with fixed amounts of enzyme in an 
appropriate reaction buffer. After incubation for ten minutes at room 
temperature, substrate (BAPNA for trypsin, 82302 for P-Factor XUa) was added 
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to the mixture and the rate of release of p-nitroanilide was monitored using a 
spectrophotometer. Absorbance at 405 nm was read at 20 second intervals for 5 
minutes. Activity of each mutant inhibitor was compared with wild-tjnpe 
inhibitor in this manner. Results were plotted using an Excel spreadsheet 
(Microsoft, Inc.) with percent residual activity versus amount of inhibitor. 
Hydrolysis Experiments 
Mutant and wild-type inhibitors were incubated with, separately. Trypsin 
and Factor XII3 for 24 hours at room temperature in an appropriate reaction 
buffer (modified firom Longstafif et al., 1990). Equal amounts of inhibitor with no 
enz3mie were incubated with reaction buffer. Enzjone with no inhibitor in 
reaction buffer was also incubated. After 24 hours the separate reactions were 
resolved using SDS-PAGE. 
Dissociation Constants 
Kj was calculated for each inhibitor in each experiment. The method used 
was described by Bieth (1974), which attempts to take into accoimt the decrease 
of available inhibitor due to extremely tight binding of inhibitor to enzyme. The 
ratio of initial inhibitor concentration to bound enzyme was plotted against the 
fraction of unbound enzyme. The slope of this line represented K^. 
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RESULTS 
Mutagenesis 
Recombinant plasmids with mutants D45E, D45L, D45N, and D45V were 
recovered and sequencing results indicated that the correct mutant codons had 
been introduced (Table 9). 
Gene Expression and Protein Purification 
SDS-PAGE verified overexpression of the desired protein as well as 
purified product (Figure 25, A and B). 
Hydrolysis Experiments 
After 24 hours incubation with trypsin both modified (hydrolyzed) wild-
t37pe inhibitor and modified mutant D45E were present (Figure 26, Lanes 5, 3). 
Binding of these two inhibitors to trypsin helped to prevent trypsin self-
hydrolysis as seen by an apparently increased amount of the unmodified trypsin 
band in these reactions over the amount of unmodified trypsin in the incubation 
reaction with mutant D45N (Figure 26, Lane 1) and incubated trypsin with no 
inhibitor (Lane 7). D45N also showed decreased amounts of both intact and 
modified inhibitor (Lane 1). 
The same reaction showed a progression in these trends after 48 hours 
(Figure 27), evidence of the continued protection of trypsin against self-
hydrolysis, seen at its highest levels with wildt5T)e (Lane 5) and decreasingly 
with D45E and D45N (Lanes 3, 1). Mutant proteins D45V and D45L showed 
extremely faint levels of intact and modified protein as well as greatly-reduced 
amounts of unmodified trypsin (Figure 30, Lanes 1 and 3). Similar decreases in 
intact/modified protein forms were seen in experiments with Factor Xlla (Figure 
28, D45L shown in top gel, Lane 4, D45E and D45N, lower gel. Lanes 2 and 4). 
Figure 29 illustrates the presence of modified and virgin inhibitor, resulting 
from reduction of disulfide bonds between the two fragments of inhibitor 
48 
Table 9. DNA and protein sequences of wild-type and mutant inhibitors 
Fused leader sequence is italicized. Double arrowheads indicate 
reactive site bond. Mutated codons are underlined and substituted amino acids 
bolded. 
INHIBITOR SEQUENCE 
70-1 ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. .K. .A. .i?. .S. .S. .S. .C. .P. .G. .K. .S. .S. .W. .P. .H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G..V. .G. -G.-S..V..A.-K..A. .I..I..R..Q..N..P.-N..V.-K..A..V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGGACTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I. .L. .E. -E. .G. .T. .P. .V. .T. .K»»D. . E".. R. .C.. N. . R.. V. . R.. I.. W. . V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K. .R. -G..L..V..V..S..P..P..R..1..G.. 
D4 5L ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. -R. .A. .J?, .ff. .S. .S. .C. .P. .G. .K. .S. .S. .W. .P. -H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G..S..V.-A..K..A..1..1.-E.-R..Q..N.-P..N..V.-K..A.-V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGCTCTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I. .L. .E. -E. .G. .T. .P. .V. .T. .K"L. -F. -R. .C. -N. -R. .V. .R. .1. .W. .V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K. .R. -G..L..V..V..S..P..P..R..1..G.. 
D4 5V ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. .R. .A. -R. .(?. .S. .S. .C. .P. -G. .K. .S. .S. .W. .P. -H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G..V. .G. .G..S..V..A..K. .A. .1..1..E.-R..Q..N..P.-N..V.-K..A..V. . 
ATCCTGGAAGAAGGTACACCGGTTACCAAGGTCTTCAGGTGCftACAGGGTTAGGATCTGGGTT 
I..L..E..E..G..T..P..V. .T. .K»»V..F..R..C..N..R..V..R..I..W..V. . 
RACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K. .R.-G..L..V..V..S..P..P..R..1..G.. 
04 5N ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X.-R..A.-R.-S..S..S..C..P..G..K..S..S..W..P.-H..L..V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G..V. .G. .G..S..V..A..K..A..1..1.-E..R..Q..N..P.-N..V..K..A..V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGAACTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I. .L. .E. .E. .G. .T. .P. .V. .T. .K"H. .F. .R. .C. .N. .R. .V..R..I. .W. .V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K. .R. .G..L..V..V..S..P.-P..R..1.-G.. 
D4 5E ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. .R..A. -R. .(?. .S. .S. .C. .P. -G. .K..S. -S. .W. .P..H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G..S..V..A..K..A..1..1..E..R..Q..N,.P..N..V..K..A..V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGGAATTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I..L. .E..E.-G..T. - P. .V. .T. .F..R..C..N.-R..V..R..I..W..V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K..R..G..L..V..V..S..P..P..R..1..G.. 
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A 1 2 B 1 2 3 
Figure 25. SDS-PAGE showing overexpression of 
mutant proteins D45L and D45V (A) and samples 70-
1, D45L and D45V after purification (B). 
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Figure 26. Trypsin reaction with wild-
t3T)e and mutant proteins (70-1, D45E, 
D45N)- (a) indicates approximate 
location of tr3rpsin band; (b) is self-
hydrolyzed ti^psin products; 
(c)approximate location of inhibitor band. 
24 hours reaction time. 
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Figure 27. Trypsin reaction with wild-tj^pe and 
mutant proteins (70-1, D45E, D45N). (a) 
indicates approximate location of trypsin band; 
(b) is self-hydrolyzed trypsin products; 
(c)approximate location of inhibitor band. 48 
hours reaction time. 
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Fi^re 28. Factor XEEa reaction with wildtype (70-1) and 
mutant proteins. Top gel (D45L), (a) indicates approximate 
location of virgin inhibitor/mutant, (b) indicates 
approximate location of modified inhibitor/mutant. Lower 
gel, mutant proteins D45E and D45N. 
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Figure 29. SDS-PAGE illustration of the presence 
of both modified (b and c in both gels) and virgin 
inhibitor bands (Lanes 2, 3, 4). Top gel stained with 
Coomassie Blue, bottom gel silver-stained. 
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Figure 30. Tiypsin reaction with wUd-tjrpe and mutant 
proteins (70-1, D45L, D45V). (a) indicates approximate 
location of trypsin band; (b) is self-hydroljrzed trypsin 
fragments; (c)approximate location of inhibitor 
(unmodified) band. 
flanking the (hydrol3^ed) reactive site bond. The amino terminal fragment is 
approximately .5.3kD and the carboxyl terminal fragment 2.8kD. 
Inhibition Assays 
Mutants D45L, D45N and D45v were found to be poor inhibitors of 
trsnpsin as illustrated by plots of ^g of inhibitor against percent residual enzjmie 
activity (Figures 31, 32 and 33). A 10-fold increase in the amount of D45L over 
wildtype and a 20-fold increase in D45V concentration over wildtype was needed 
to reduce residual trypsin activity to 50% (Table 10). An 87-fold increase in 
D45N was necessary to reduce trypsin activity to 50% (Table 11). D45E 
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Figure 31. Inhibition assay against trypsin with 
•wildtype (70-1) compared to mutant proteins D45L and 
D45V. 
a 
ug Protein 
Figure 32. Inhibition assay against trypsin with 
wildtj^pe (70-1) compared to mutant proteins D45E 
and high concentration of D45N. 
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Figure 33. Inhibition assay against trypsin with 
wildtype (70-1) compared to mutant proteins D45E 
and low concentration of D45N. 
appeared to be as good an inhibitor of trypsin as wildtype CMTI-V (Figures 32 
and 33, Table 11). 
A 5-18 fold increase in D45L and a 6-8 fold increase in D45V were 
necessary for the same level of activity (50%) when compared with wildtype 
activity against P-Factor XTLa at concentrations of l.lE-04 - 2.4E-04 (Table 12). 
At low mutant concentrations (<.02^g) little inhibitory activity was seen by 
D45N, with good inhibition measured at higher (0.3//g) inhibitor concentrations 
(Table 13). Mutant D45E was a good inhibitor of both enzjnnes, with activity 
levels comparable to that of wildtype. Results against Factor XHgare plotted in 
Figures 34 and 35. 
Dissociation Constants 
Increases in Kj (41-52 fold) were seen for mutants D45L and D45V versus 
wildtype inhibitor against trypsin (Table 14). Increases of 85-100 fold were 
measured for D45N. A decrease in Kj was measured for D45E when compared 
with wildtype (1-4 fold). Against P-Factor Xlla (Table 15) increases in Kj ranged 
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Table 10. Inhibitor necessary for 50% residual trypsin activity of protein) 
Trypsin Concentration Inhibitor //g of Protein Increase 
8.3E-05 M 
70-1 0.30 
(See Figure 30) D45L 3.00 lOX 
D45V 6.00 20X 
Table 11. Inhibitor necessary for 50% residual trypsin activity (^g of protein) 
Trypsin 
Concentration Inhibitor /^g of Protein 
Increase/ 
(Decrease) 
2.5E-04 70-1 0.04 
(See Figure 32) D45E 0.03 (L3X) 
D45N n.d. 
1.7E-04 70-1 0.03 
(See Figure 31) D45E 0.06 (2X) 
D45N 2.6 87X 
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Fi^re 34. Inhibition assay against P-Factor XII, with 
wildtype (70-1) compared to mutant proteins D45E and 
D45N. 
Table 12. Inhibitor necessary for 50% residual P-Factor XEIa activity (in /ug of 
protein) 
Factor XEIa Inhibitor //g of Protein Increase 
2.3E-04 70-1 n.d.® 
D45E 0.3 
D45N 0.3 
1.7E-04 70-1 0.03 
(See Figure 34) D45E 0.04 1.3X 
D45N n.d. 
"Not determined 
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Figure 35. InhibitLon assay against p-Factor XEg with 
wildtype (70-1) compared to mutant proteins D45L and 
D45V. 
Table 13. Inhibitor necessary for 50% residual P-Factor Xlla activity (in iig of 
protein) 
Factor Xlla Inhibitor //g of Protein Increase 
l.lE-04 70-1 0.1 
(See Figure 33) D45L 0.5 5X 
D45V 0.6 6X 
2.4E-04 70-1 0.2 
D45L 3.6 18X 
D45V 1.6 8X 
between 12-30 fold for mutants D45L and D45V and 2-62 fold for mutants D45E 
and D45N. This suggested a decrease in the ability of the mutant inhibitors to 
bind tightly to trypsin in all cases except for D45E, with a somewhat reduced 
loss of binding abihty of all mutants for P-Factor Xlla. 
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Table 14. Dissociation constants (Kj) for trypsin in presence of inhibitors; 
mutants compared with wildtype (in molar concentrations) 
Enz3ane 
Concentration Inhibitor 
Dissociation 
Constant (Ej) 
Increase/ 
(Decrease) 
Trypsin, 8.3E-05M 70-1 1.4E-08M 
D45L 9.0E-07M 64X 
D45V 1.2E-06M 86X 
Trj^psin, 1.7E-04M 70-1 4.3E-09M 
D45E 3.6E-09M (1-2X) 
D45N n.d." 
Trypsin, 2.5E-04M 70-1 2.2E-10M 
D45E 1.5E-09M (6.8X) 
D45N n.d. 
"Not determined 
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Table 15. Dissociation constants (Kj) for P-Factor Xlla in presence of inhibitors; 
mutants compared with wildtype (in molar concentrations) 
Enz3nne 
Concentration Inhibitor 
Dissociation 
Constant (Kj) Increase 
Factor Xn, 1.1E-04M 70-1 1.4E-08M 
D45L 2.2E-07M 16X 
D45V 5.3E-07M 38X 
Factor XII, 2.5E-04M 70-1 1.3E-08M 
D45L 3.5E-07M 27X 
D45V 1.3E-07M lOX 
Factor Xn, 2.3E-04M 70-1 8.4E-10M 
D45E 4.1E-08M 48X 
D45N 3.4E-08M 40X 
Factor xn, 1.7E-04M 70-1 3.2E-09M 
D45E 6.2E-09M 2X 
D45N 3.1E-08M lOX 
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DISCUSSION 
The results of these experiments suggested that the mutant proteins 
D45L, D45V and D45N apparently function more as a substrate than an 
inhibitor. In an attempt to explain these, we studied the mechanisms thought to 
underlie serine proteinase function, which is one of the best-understood enzyme 
famihes. Serine proteinases have three requisite residues in close proximity in 
their tertiary, though not primary, structure: Asp, His, Ser (referred to by the a-
chymotrypsin numbering standard as Ser 195, His57 and Asp 102). These three 
residues are designated as the catalytic active site of the enzyme. Three other 
important sites are important to the complex formed, described by example 
between trsrpsin and an ovomucoid inhibitor (Bode and Huber, 1992): 
• an area of loose binding through main-chain H-bonds between enzyme 
and P2, P3, and P4; 
• a specificity pocket into which the PI residue side chain fits; and 
• the oxyanion hole which stabilizes the main chain carbonyl group of the 
reactive bond. 
The reaction proceeds as follows: upon entering the active site, the 
carbonyl oxygen of the PI residue fits into the oxyanion hole, stabilized by H-
bonds with the amide groups of Ser 195 and Glyl93. In general,there are two 
main steps involving the reactive site bond, His57 and Ser 195. 
Acid-catalyzed nucleophilic acyl substition - a transfer of Serl95's 
hydroxyl H to His57 is simultaneous with a nucleophilic attack by the hydcoxyl 
O on the reactive bond's carbonyl carbon. This leads to a transitional state in 
which the reactive bond carbonyl O is stabilized in the oxyanion hole and during 
which a tetrahedral intermediate is formed. The subsequent donation of a 
proton by His57 to the reactive bond amide group is accompanied by formation 
of an acyl-enzjnne intermediate, and the carboxyl fragment of substrate is 
released. 
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Hydrolysis of the enzyme ester - In the second step, His57 attacks the 
hydrogen of a water molecule as the water molecule oxygen attacks the carbonyl 
carbon of the acyl enzyme intermediate, leading to the formation of a carboxyHc 
acid group, reforming of the enzjnne, and release of the amino terminal 
substrate fragment. 
A closer look at the oxyanion hole shows the carbonyl oxygen stabilized in 
the hole through hydrogen bonding interactions with the amide groups of 
Gly 193 and Serl95 (Figure 32, adapted from Garrett and Grisham, 1995). As 
the acyl enzyme intermediate is formed, this stabilization is increased through 
two effects: the lengthening of the carbonyl bond upon change from a single to a 
double bond (123 pm vs. 143 pm), bringing the oxygen closer to the amide 
Figure 36. The oxyanion hole, with the carbonyl 
oxygen of the reactive site bond positioned within. 
(A) before formation of the covalent intermediate, 
and (B) after formation of the covalent 
intermediate. 
A 
B 
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groups; and a strengthening of these bonds by the introduction of a charge on 
the oxygen. 
An inhibitor is thought to either freeze the complex at some point, surely 
before release of the amino product, and possibly before cleavage of the reactive 
site bond, or maintain a position such that the reactive site bond can be 
continuously broken and reformed. Laskowski and Kato (1980) suggest that the 
scissile bond is cleaved but that dissociation does not occur. We believe the most 
logical explanation for the loss of inhibitor function throu^ removal of the 
negatively-charged PI' is through the restriction of conformational change while 
the inhibitor is in complex with the target enzyme. The negatively-charged PI' 
side chain is involved in extensive electrostatic interactions with inhibitor core 
residue side chains that may restrict rotational side chain movement, thereby 
fixing the main chain into position. Eglin c structural determinations indicate 
that when inhibitor is free, the charged Asp side chain points toward the 
solvent, as expected (Hyberts et al., 1992, Hipler et al., 1992). In bound Eglin c 
(Bode et al., 1986), however, the Pi' side chain is rotated inward toward the 
inhibitor core, and is involved in electrostatic interactions (see Figures 9-12). 
This same effect is seen in free vs. bound structures of CI-2 and is part of an 
Figure 37. Electrostatic/H-bonding network of Eghn c in 
complex with subtilisin. 
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extensive stabilizing network of hydrogen bonding and electrostatic interaction 
involving the P2 Thr, the P3', P6' and P8' Arg, the amino group of the terminal 
chain residue, and a tightly-bound water molecule (McPhalen and James, 1988) 
(Figure 37). Within the Potato 1 inhibitor family the P2 Thr is fully conserved, 
as are the P6' and P8' Arg residues (see Table 6). Previous experiments in this 
laboratory have shown that replacement of the P6' and P8' Arg residues alters 
function as foUows. 
The P3' Arg residue was replaced with Ala and Gin, both of which showed 
a slight increase in activity toward trs^psin. The P6' residue was replaced with 
Ala, Lys and Gin, with only the Ala mutant showing a slight decrease in activity 
toward trypsin. No measurable changes against trs^sin were found with 
mutants in which the P8' Arg was replaced by Ala, Lys, or Gin. Against P-Factor 
XUa, however, replacement of any of the Arg by Ala resulted in a decrease in 
activity ranging from 10-20 fold, and replacement of the P6' Arg by Lys or Ghi 
also resulted in lowered activity (Table 16). Additionally, replacement of the P2 
Thr by Ala resulted in a mutant with approximately 10% and 20% activity of 
wildtype against P-Factor Xlla and trypsin, respectively (Wen et al., 1993). 
Similar results have been reported for other members of the Potato I inhibitor 
family, and apparently this rigid network is essential to inhibitory function, 
although the exact role the rigidity plays is still under discussion. Warshel et al. 
(1989, p. 3630) suggest that serine proteinases function by "providing 
electrostatic complementarity to the changes in charge distribution occurring 
during the reaction they catalyze". 
The network is supported at one end by the P2 and PI' residues. The PI 
side chain is fixed into the specificity pocket of the enzyme. Specificity may 
actually be a side effect of stabilization, however; alterations of this side chain 
usually result in "spedficit}^ changes i.e., loss of specificity is actually a loss of 
function. At the other end, the network is supported by side chains of the P3', 
P6', and P8' residues, and the terminal residue amino group. Loss of either of 
66 
the P2 or Pi' residues collapses the network. On the other hand, the more 
extended components of the other end of the network may be more resilient to 
change. Only when the center (PeO Arg residue is replaced, which provides, 
along with the P2 and PI' residues, a three-point tensional effect centered at the 
bound water molecule, does the network coUapse. 
The next question is; how exactly does the network function? Loss of 
activity of our D45L, D45N and D45V mutants might be explained in one of two 
ways: 
Table 16. Previously-Studied mutants and their inhibitory activities (from Wen 
et al., 1997). Inhibitor necessary for 50% residual enzyme activity 
Inhibitor Tr37psin P-Factor XUg 
R47A(P3') SLIGHT INCREASE lO-FOLD 
R47Q SUGHT INCREASE ND" 
R50A (peo 2-FOLD 20-FOLD 
R50K ND 9-FOLD 
R50Q ND 3-FOLD 
R52A(P8') ND 11-FOLD 
R52K ND ND 
R52Q ND ND 
"No Difference 
• the wildtype negatively-charged PI' residue might act in concert with the 
other residues involved in this network to provide stabOization of the 
flexible loop that functions in a general manner to binding of enzyme; or 
• as a key factor, along with the PI side chain, in preventing proper 
alignment of the main chain reactive site components into (or out of) the 
oxyanion hole which leads to substrate hydrolysis. Thus, remaining 
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network residues function as a positioning network for the PI' side chain; 
the enzyme spedficity pocket functions as a positioning network for the 
PI side chain. In effect, the inhibitor has beaten the enzyme at its own 
game of stabilization. 
Thus, hydrolysis requires the fixation of torsional angles at the amino 
side of the reactive site bond with a level of conformational freedom for torsional 
angles at the carboxyl side of the reactive site bond. A comparison of the 
backbones of several determined Eglin c structures supports the concept of 
needed conformational change of substrate main chain that, in inhibitor, is 
prevented. While free E^in c main chain conformation shows a somewhat 
variable conformation, when bound, the main chain conformation is fixed into a 
position different than that of any firee structures. This is additionally 
supported by an E^in c double mutant, L45R/D45S, (Pl/Pl*) which exhibited 
substrate-like behavior and higher mobihty of the sdssile bond N—vector 
(Heinz et al., 1992). 
68 
PART n. ANALYSIS OF P3 MUTANTS 
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INTRODUCTION 
The tertiary structures of the small serine proteinase inhibitors are quite 
similar in spite of their primary sequence variations. The binding loop is held 
rigid against the compactly-folded core. It has been suggested that the rigidity 
of the inhibitor while in complex with the enzyme, in contrast to the more 
flexible substrate, may result in tighter binding and slower release. In most 
serine proteinase inhibitors the P2 or P3 position is occupied by a Cys residue 
whose disulfide bridge with a core residue is thought to have an important 
stabilizing effect on the inhibitor-enz3nne complex (Bode and Huber, 1991). In 
the Potato I family the binding-loop Cys is absent and the P3 position has a fuUy 
conserved hydrophobic residue (see Table 6). Stabilization of the rigid inhibitor-
enzjnne complex is believed to be a result of extensive electrostatic and 
hydrogen-bonding interactions between binding loop and core residues 
(Laskowski and Kato, 1980). 
We studied the fully conserved hydrophobic residue at the PS position. Its 
side chain has not been shown to have a specific enzjnne residue interaction site 
but is thought to be involved in hydrophobic interactions with other inward-
fadng inhibitor side chains (McPhalen and James, 1988). We substituted the 
following residues for CMTI-Vs P3 Val: Gly, Met, and Ser. Preliminary 
modeling suggested possible interactions of these newly introduced side chains 
(see Figures 19-21). Met's bulky side chain would probably be prohibited fi:om 
these interior interactions due to close contacts. Although neither Gly nor Ser 
would encounter steric hindrances, the Gly substitution would result in a loss of 
interior hydrophobic interactions and increased flexibihty of the inhibitor 
backbone chain in that area. If Ser's side chain is forced into the interior, it may 
disrupt already-existing hydrogen-bonding and electrostatic interactions that 
are necessary to inhibitor function. 
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METHODS 
Mutagenesis 
A PGR overlap extension method (Ho et al., 1989) was used to create site-
spedfic mutations in the internal regions of CMTI-V (see Figure 24). 
Overlapping pairs of synthetic oligomers containing internal sequences 
including the desired base substitutions were designed such that the following 
amino add substitutions were introduced at position 42 (P3): Met, Gly or Ser. 
Mutagenic ohgonudeotides were custom-synthesized by Keystone Laboratories 
(Menlo Park, CA) (Table 17). The PGR overlap extension consisted of three 
steps. In the first (mutational) step, PGR was used in two separate reactions per 
mutant, each involving: a single mutagenic oligomer (eitlier forward or reverse); 
a flanking primer; and a template (recombinant DNA isolated from wild-type 
GMTI-V Glone 70-1). This done was in the plasmid pGEX (pGEX70-l) in the E. 
coli host JM109. The flanking primer was either 5* Bam or 3' PTI (Wen et al., 
1993). In the second step, the overlapping fragments were annealed and 
extended. In the final step the mutated fragment was £unplified using PGR. 
The fiiU-length DNA was recovered and digested with Bam HI. The insert 
was gel purified and ligated to pT7-7 with T4 DNA Hgase (New England 
Biolabs). The ligation products were transformed into E. coli strain JM109. 
Table 17. Sequences of mutagenic oligomers for PGR overlap extension 
method. For each set of mutants both forward (F) and reverse (R) primers 
are indicated. Mutagenic codons are bolded. 
MUTANT MUTAGENIC OUGOMER 
V42M(F) 5'-G-GAA-GAA-GGT-ACA-CCG-ATG-ACC-AAG-GAC-3' 
V42M(R) 5'-GCA-CCT-GAA-GTC-CTr»GGT-CTT-CGG>TGT-ACC-T-3' 
V42S/G (F) 5'-G-GAA-GAA-GGT-ACA-CCG-(A/G)GT.ACC-AAG-GAC-'ITC-
3' 
V42S/G (R) 5'-GCA-CCT-GAA-GTC-CTr-GGT-AC(C/T)-CGG-TGT-ACC.T-3' 
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Sin^e colonies were transferred to a gridded plate with media containing 100 
;/g/ml ampidUin, and recombinant colonies selected using colony/plaque screen 
membranes (DuPont) and ^^-labeled 70-1 insert (Multiprime DNA Labelling 
System, Amersham). Plasmids &om positive colonies were sequenced using the 
Sequenase Quick-Denature Plasmid Sequencing Kit GJnited States 
Biochemical). Sequencing results were analyzed using the sequence analysis 
software "Seqaid" (Rhoads and Roufa, 1989). Complete sequencing of each 
strand was done to verify that the mutated sequence was present in the proper 
orientation and with the correct sequence. 
Expression of Mutant Genes 
The mutant sequences were subcloned into the BamHI site within the 
multi-doning site of the expression vector pT7-7, which contains the T7 
promoter and is dependent on T7 RNA polymerase for target gene expression. 
The recombinant vector with the correct sequence was transformed into the E. 
coli host BL21(DE3), with the T7 RNA polymerase gene under control of the 
ZacZ promoter (Studier et al., 1990). The promoter is inducible through the 
addition of isopropyl-l-thio-P-D-galactoside (EPTG). Cells feom one colony 
containing the recombinant DNA were transferred sind cultivated overnight in 
LB broth with 200 //g/ml ampidUin. The cell culture was diluted 1:10 and then 
placed once again at 37°C at 200 rpm vmtil an O.D.600 of 0.6-0.7 was reached. 
IPTG (1.5 mM) was added to the cidture and the cultures remained on the 
shaker for an additional four hours. Cells were harvested by centrifugation at 
4000xg for ten minutes at 4°C. A sonication/cooling cyde system was used 
followed by centrifugation at 4°C for 30 minutes at 16,000xg to obtain cell-free 
extract. Over-expression of the proteins was verified by SDS-PAGE, and an 
antibody affinity column was used to isolate the recombinant proteins. Protein 
purity was checked using SDS-PAGE. 
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Inhibition Assays 
The mutant and wild-type inhibitors were tested against bovine trypsin 
(Sigma) and human P-Factor Xlla (Calbiochem). Residual activity of a given 
proteinase was measured after incubation with inhibitor (Wen et al., 1993). 
Various amounts of inhibitor were mixed with fixed amounts of enzyme in an 
appropriate reaction buffer. After incubation for ten minutes at room 
temperature, substrate (BAPNA for trj^sin, S2302 for P-Factor XEEJ was added 
to the mixture and the rate of release of p-nitroanilide was monitored using a 
spectrophotometer. Absorbance at 405 nm was read at 20 second intervals for 
five minutes. Activity of each mutant inhibitor was compared with wild-t3T)e 
inhibitor in this manner. Results were plotted as percent residual activity 
versus concentration of inhibitor for each enz3ane. 
Hydrolysis Experiments 
Mutant and wild-type inhibitors were incubated with, separately, trypsin 
and Factor XUg for 24 hours at room temperature in an appropriate reaction 
buffer. Equal amounts of inhibitor with no enzyme were incubated with 
reaction buffer (modified firom Longstaff et al., 1990). Enzjnne with no inhibitor 
in reaction buffer were also incubated. After 24 hours the separate reactions 
were resolved using SDS-PAGE. 
Dissociation Constants 
Kj was calculated for each inhibitor in each experiment. The method used 
was described by Bieth (1974), which attempts to take into account the decrease 
of available inhibitor due to extremely tight binding of inhibitor to enzjnne. The 
ratio of initial inhibitor concentration to bound enzyme was plotted against the 
fraction of unbound enzjrme. The slope of this line represented Kj. 
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RESULTS 
Mutagenesis 
Recombinant plasmids of mutants V42G, V42M, and V42S were recovered 
and sequencing results indicated that the correct mutant codons had been 
introduced (Table 18). 
Table 18. DNA and protein sequences of wild-type and mutant inhibitors 
Fused leader sequence is italidzed. Double arrowheads indicate 
reactive site bond. Mutated codons are underlined and substituted amino acids 
bolded. 
INHIBITOR SEQUENCE 
70-1 ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. .H. .A. .R. -G. .S. .S. .C. .P..G. .K. .S. .S. .W. .P. .H. -L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCXATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G. .S. .V. .A. .K. .A. .1. .1. .E. .R. .Q. .N. - P. .N. .V. .K. .A. .V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGGACTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I. .L. .E. .E. .G. .T. .P. .V. .T. .K"D. .F. .R. .C. .N. .R. .V. .R. . I. .W. .V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N..K..R. .G.-L..V..V..S..P..P..R..1. .G. . 
V42G ATGGCTAGAAITCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. . r. .R. . A. .R. .G. .S. .S. .C. .P. .G. .K. .S. .S. .W. - P. .H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G. .S. .V. .A. .K. .A. .1. .1. .E. .R. .Q. .N. .P. .N. -V. .K. .A. .V. . 
ATCCTGGAAGAAGGTACACCGGTTACCAAGGGTTTCAGGTGCaACAGGGTTAGGATCTGGGTT 
I..L..E..E..G..T..P..V..T. .K»»G. .F. .R. .C. .N. .R. .V. .R. . I. .W. .V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N. .K..R..G..L..V..V..S..P..P..R..I..G. , 
V4 2M ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. . J. .R. .A. .R. .G. .S. .S. .C. .P. .G. .K. .S. .S. .W. .P. .H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G. .S. .V. .A. .K. .A. .1. .1. .E. .R. .Q. .N. .P. .N. .V. .K. .A. .V.. 
ATCCTGGAAGAAGGTACACCGGTTACCAAGATGTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I. .L. .E. .E. .G. .T. .P. .V. .T. .K»»M. .F..R. .C. .N. .R. .V. .R. .1. .W. .V.. 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N. .K..R..G..L..V..V..S..P..P..R..1. .G. . 
V4 2 S ATGGCTAGAATTCTCGCCCGGGGATCCTCCTGCCCAGGTAAGTCATCATGGCCACACCTGGTA 
A. .R. .X. .R. .A. -R. .G. .S. .S. .C. .P..G. .K. .S. .S. .W. .P. .H. .L. .V. . 
GGTGTTGGTGGTTCCGTTGCTAAGGCTATCATCGAAAGGCAGAATCCGAACGTTAAAGCTGTT 
G. .V. .G. .G. .S • .v. .A. .K. .A. .1. .1. .E. .R. .Q. .N. .P. .N. .V. .K. .A. .V. • 
ATCCTGGAAGAAGGTACACCGGTTACCAAGAGTTTCAGGTGCAACAGGGTTAGGATCTGGGTT 
I..L..E..E..G..T..P..V..T. .K»»S. . F. .R. .C. .N. .R. .V. .R. . I. .W. .V. . 
AACAAGAGAGGTCTGGTAGTATCACCACCGAGGATCGGT 
N. .K..R..G..L..V..V..S..P..P..R..I..G. . 
74 
Gene Expression and Protein Purification 
SDS-PAGE verified overexpression of the desired protein as well as 
purified product (Figure 38). 
Hydrolysis Experiments 
After incubation with trypsin modified wild-type inhibitor and mutant 
inhibitors (in smaller amounts) V42G, V42M and V42S were present (Figure 40, 
Lanes 3, 5, 7 and 9 ). Tight binding of enzyme by wildtj^je and mutant protein 
V2S prevented trypsin self-hydrolysis, with a lesser effect seen for mutants 
V42G and V42M (Lanes 5 and 7). The trypsin band is absent firom unprotected, 
self-hydrolyzed tr37psin (Lane 2). 
U1 O O (M (M (M (N (M 
> > > > > > 
A B 
Figure 38. SDS-PAGE showing overexpression of 
mutants V42S, V42G and V42M (A) and purity of 
proteins after purification (B). (a) indicates 
approximate location of the inhibitor protein band. 
75 
CQ cd cd 
X X 
1— -I 
X! 
•82 -r S! W 53 Cd g 6 ^ ^  fe«> ® > > > 
46 kD 
30 kD 
21.5 kD 
14.3 kD 
6.5 kD 
3.4 kD 
1 2 3 4 5 6  7 8 9  1 0  
Figure 39. Silver-stained SDS-PAGE resxdts of hydrolysis 
experiments of wild-type and mutant proteins against P-Factor 
(a) and (b), approximate positions of large and small fragments of 
modified inhibitor. 
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Figure 40. Hydrolysis experiment, trypsin with wild-type 
inhibitor and mutant proteins V42G, V42M, and V42S. 
(a) approximate location of trypsin band, (b) approximate 
location of modified inhibitor band Oarge fragment) and 
(c)small fragment of modified inhibitor. 
Similar residts were seen with inhibitors against P-Factor Xlla (Figure 
39). The amount of hydrolyzed inhibitor (both wildtype and mutant) was 
apparently less than foimd against Trypsin. 
Inhibitioii Assays 
Mutants V42G, V42M and V42S were found to be good inhibitors of 
trypsin and P-Factor Xlla as illustrated by plots of inhibitor concentration in 
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micrograms versus percent enzyme residual activity (Figures 41 and 42). It was 
found that little change in mutant protein concentrations versus wild-t3i)e 
inhibitor was necessary for reduction of enz3rme activity to 50% for both trjrpsin 
and P-Factor XE, (Tables 19 and 20). 
Figure 41. Inhibition assay against trypsin with 
wildtype (70-1) compared to mutant proteins V42G, 
V42MandV42S. 
0.02 0.04 0.06 0.06 0.1 
ugRrotein 
0.12 0.14 0.16 
Figure 42. Inhibition assay against P-Factor XHa with 
wildtype (70-1) compared to mutant proteins V42G, V42M 
andV42S. 
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Table 19. Inhibitor necessary for 50% residual P-Factor XUa activity (Aig of 
protein). 
P-Factor Xlla 
Concentration Inhibitor /^g of Protein 
Increase/ 
(Decrease) 
2.3E-04 70-1 <.01 n.d.^ 
V42G .01 n.d. 
V42M .01 n.d. 
V42S .02 n.d. 
1.7E-04 70-1 .03 
(See Figure 41) V42G .08 2.7X 
V42M .05 1.7X 
V42S .02 (1.5X) 
' n.d. - not determined 
Table 20. Inhibitor necessary for 50% residual taypsin activity (ug of protein) 
Trypsin Increase/ 
Concentration Inhibitor ^ug of Protein (Decrease) 
1.7E-04 70-1 0.04 
(See Figure 40) V42G 0.08 2X 
V42M 0.06 1.5X 
V42S 0.04 IX 
2.5E-04 70-1 0.02 
V42G 0.04 2X 
V42M 0.06 3X 
V42S 0.04 2X 
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Dissociation Constants 
Little change in was seen for mutants V42G, V42M and V42S versus 
wildtype (Table 21) for the trypsin assay. Dissociation constants ranged &om a 
6-fold decrease to a 3.7-fold increase. Similarly, a range of a 1.1-fold decrease to 
a 3-fold increase was seen for the mutants with P-Factor Xlla (Table 22). 
Table 21. Dissociation constants (Kj) for P-Factor Xlla in presence of inhibitors 
(in molar concentrations). 
Dissociation Increase/ 
Enzyme Concentration Inhibitor Constant (IQ (Decrease) 
2.3E-04 70-1 8.4E-10M 
V42G 2.5E-09M 3X 
V42M 1.2E-09M 1.4X 
V42S 1.9E-09M 2.3X 
1.7E-04 70-1 3.2E-09M 
V42G 7.8E-09M 2.4X 
V42M 4.2E-09M 1.3X 
V42S 2.8E-09M (1-lX) 
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Table 22. Dissociation constants (Kj) for trypsin in presence of inhibitors (in 
molar concentrations). 
Dissociation Increase/ 
Enzyme Concentration Inhibitor Constant (K;) (Decrease) 
1.7E-04 70-1 4.3E-09M 
V42G 2.1E-09M (2.1X) 
V42M 6.6E-10M (6.5X) 
V42S 7.2E-10M (6X) 
2.5E-04 70-1 2.2E.10M 
V42G 4.1E-10M 1.8X 
V42M 2.3E-10M IX 
V42S 8.1E-10M 3.7X 
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DISCUSSION 
The results of our inhibition activity assays suggest that mutation of the 
Val residue at the P3 position of CMTI-V to residues such as Ser, Gly and Met 
makes little difference to the level of inhibitory activity against both trypsin and 
P-Factor Xlla. These results seem to be at odds with the fact that the Val 
residue is almost fuUy conserved at that position in the Potato I family of serine 
proteinase inhibitors (see Table 6). 
Hydrophobic residues are known to be important to protein folding and 
stability (Creighton, 1993). In most studies of hydrophobidty as a determinant 
of protein stability, the structures involved are tightly-packed cores with little or 
no exposure to solvent (Otzen et al., 1995). However, hydrophobic residues are 
often present and highly conserved in structures partly accessible to solvent. 
This fact, in conjunction with observations that substitution of non-hydrophobic 
residues with no effect on their inhibitory activity (seen in data in the present 
study and in Otzen et al., 1995) suggests they may play an important role in 
other inhibitor functions, such as protein stability. 
Most inhibitors of serine proteinase belonging to the same family show a 
high degree of conservation of teritary, though not primary, structure. In fact, 
it's been shown that most members of a family exhibit a degree of primary 
structural hypervariabiUty with that region of inhibitor that interacts most 
closely with enzsone - the flexible loop region (Laskowski, 1987). However, in 
the case of the Potato I family of inhibitors, hypervariability has been shown to 
not exist (Beuning et al., 1994). Their analysis, however, was based on a series 
of closely-related sequences from the same family of proteins (8 isoinhibitors 
from potato, 3 from tomato, 4 from tobacco, 2 from squash, 7 from barley, and 
one each from leech and yeast). It may be even more revealing to compare 
sequences from only discreet sources regardless of family. 
A sequence similarity search of a sequence within the flexible loop region 
of CMTI-V, -PVTKDFRCNRVRI- (P4-P9') against the SWISS-PROT database in 
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March of 1997 yielded 101 related entries. At least 20 of these entries £ire 
apparently unique isolates from separate species, and are Hsted in Table 23. 
These sequences indicate a hi^ conservation of homology of hydrophobic 
residues at positions equivalent to CMTI-Vs P3, P2', P7', P9', PlO', P17', P18' 
and P23'. In CMTI-V these positions are occupied by V42, F46, V51,153, W54, 
V61, V62, and 167. Residues V42, F46,153, W54 and 167 may be involved in 
what Otzen et al. (1995) refer to as a "hydrophobic minicore". The positions of 
these residues are shown in Figure 43, with a stereoview presented in Figure 44. 
Table 23. Sequence similarities of proteins from discrete sources based on the 
search sequence -PVTKDFRCNRVRI-
CMn-v" V I L E B G T P V T K D F R C N R V R I W V  N K R G L V V S P P R I G  
Momardca chBfanOa'' V  I  I  K  V  G  S  6  A  T  K  D  F R C D R V R V W V  T  E  R  G  I  V  A  R  P  P  T I G  
FagopynmesaJentum' I  V  L  P  E  G  S  A  V  P  R  D  L R C D R V W V F V  D  E  R  G  V  V  V  D  T  P  V  V  M  
Amaranthustvpochcjnciiacus'' I  V  K  H  E  R  S  G  F  T  K  D  F R C D R V W V V V  D  Y  T  G  V V  V  R  T  P  R  V  T  
Salanmtii>erosum' Q  I  L  L  N  G  S  P  V  T  M  D  X R C N R V R I i F D  N  I  L  G  D  V  V  Q  I  P  R  V  A  
Lycopersicum pemviana' p  I  L  L  N  G  S  P  V  T  K  D  F R C D R V R L F V  N  I  L  G  D  V  V  Q  I  P  R  V  T  
Sambucusni '^ Q  I  L  L  N  G  S  P  V  T  M D  X R C N R V R L F D  N  I  L  G  D  V  V  Q  I  P  R  V  A  
ArabiapeisthaBana'' V  I  V  P  E  G  S  I  V  T  T  D  E R C D R V R V W V  D  E  N  G  I  V  T  R  V  P  V  I  G  
fitcotiana^fvBsbis' S  V  I  L  D  G  S  P  V  T  T  D  F R C D R V R V F V  D  G  N  R  I  V  V  K  T  P  K  S  G  
MoaUanaspJ P s V  L  N  G  S  P  V  T  K  D  F R C E R V R L F V  N  V  L  D  F  V  V  Q  I  P  R  V  G  
HordeunviJgaris'' P  s  V  L  N  G  S  P  V  T  K  D  F R C N R V R L F V  N  V  L  D  V  V  V  Q  I  P  R  V  G  
LycoperskurtesaJentum' L  M  p  R  G  Q  N  W  A  T  K  D  X R P N R V R V F N  D  D  S  G  K  V  N  S  I  P  R I G  
VUntersquash'" V V I. P V G S V V  T  A  D  X R P N R V R V F N  D D S G K V K S I P R I G  
Tea mays" Q T V L N G T P  V  T  E  D  L R C N R V R L F V  N V I. D F V V Q T P Q V G 
Phaseokjs angu/aris" Q V s P H D S F  V  T  A  D  X N P K R V R L Y V  D E s N K V T R T P S I G 
83 
Val42 
Phe46 
Figure 43. CMTI-V and possible hydrophobic minicore form by 
interactions of partly-exposed hydrophobic sidechains of residues Val42, 
Phe46, ne53, Trp54 and He 67. 
Figure 44. Stereoview of CMTI-V with residues 
indicated in Figure 42. 
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These residues interact in the following manner, based on measurements 
from the derived structure of CMTI-V in solution (Cai et al., 1995a). The base 
minicore involves three nearby residues (Table 24): Val42, Phe46 and Trp54. 
Val42 seems to be the central attractant for both Phe46 and Trp54. Trp54 and 
Phe46 have fewer dose contacts, and Leu36 and ne67 may play a secondary 
supportive role in their interactions with Phe 46 and Trp54 (Table 25). Their 
possible role in protein stability is supported by work done by Otzen et al. (1995) 
and a minicore in the Potato I fgunily inhibitor CI2. They studied 3 loop 
residues, Val57(P3), Leu51(P9) and Phe69 (PIO'). Sin^e and multiple mutants 
of these residues showed stabilization of the protein, as measured by resistance 
to denaturation by guanadinium chloride, decreased as hydrophobic groups were 
lost. 
If there are subtle differences in function based on the loss of hydrophobic 
interactions, then another approach is to investigate the evolutionary processes 
that might result in the conservation of residues that apparently seem 
unimportant to functional inhibitory activity. The flexible loop of these tj^pes of 
inhibitors are often highly hydrophobic, as is the case with CMTI-V. To study 
the P3 Val in itself does not take into account the fact that it may be psirt of a 
group effect that can tolerate substitutions up to a certain point. For example, a 
hydrophobic network of several residues may be optimal for inhibitor function. 
Loss of one residue may not significantly alter function; loss of a second and/or 
third residue may, e.g., alter function somewhat. Loss of a fourth or fifth 
residue may result in loss of function. 
Another interesting aspect to our current studies is suggested by the 
hydrolysis experiments with mutants V42G, V42M and V42S compared with 
wild-tjTpe 70-1 against tr5T)sin (Figure 39). In all hydrolysis experiments with 
trypsin we were able to visualize an unmodified band of taypsin, protected from 
self-hydrolysis, by virgin or modified inhibitor. However, mutants V42G and 
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Table 24. Listing of atom-to-atom distances (A) between Trp54 and Phe46, 
Phe46 and ILe67, and Trp54 and LeuSG. 
Trp54/Phe46 Phe46/Ile67 Phe46/Ile67 Trpo4/Leu36 Trp54/Leu36 
HC2 (4.00) Hel Ha (3.83)He2 CC2 (4.o8)HC2 C51 (4.80)CC Cfi2(4.99)C52 
Nel (4.00) Hel Ho (4.32)Ce2 CCl (4.41)H62 C61 (4.80)NC1 C62(4.49)Ha 
Hel (4.00) Hel Ha(3.90)H62 CCl (4.89)C62 C61 (3.84)C62 C62(4.97)CC2 
Hel (4.00) Cel Ha(4.36)C62 CCl (3.47)He2 C61 (3.79)C€2 C62(4.93)Ce2 
Hel (4.00) CCl CC2 (4.97)C52 CCl (4.46)Ce2 C61 (3.3o)CC2 
Hel (4.00) HCl CC2 (4.06)H62 C51 (2.91)Cti2 
V42M show a fairly large decrease in level of protection of trypsin against self-
hydrolysis, with a somewhat smaller decrease seen for V42S (Lanes 5, 7,and 9) 
suggesting that although activity levels may not be greatly altered, there may be 
some difference in the tightness of binding to enzyme. During the enzyme 
inhibition assays, inhibitor and enzyme were allowed to eqiulibriate (i.e., bind) 
before the addition of substrate. The residual activity of enzyme measured could 
be due to various possible explanations: 
• inhibitor was bound tightly to enzyme with no or extremely slow release, 
thus effectively blocking blading of substrate to enzyme; 
• inhibitor does bind more tightly to enzyme than does substrate, and is 
released more slowly. However, the residual activity levels are most 
affected by the fact that inhibitor has a higher affinity for enzyme binding 
than does the substrate. In this case, substrate would be "outcompeted" 
for enzjrme space, rather than being ftdly blocked from binding. 
These may be subtle differences, but might be reflected in different 
observations. For example, residual activity results may show no difference 
between mutant and wildt3^e if the second explanation were correct. However, 
the decreased levels of unmodified tr3i)sin during hydrolysis experiments might 
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suggest that although the mutant inhibitors retained a high affinity for enzjone, 
they were unable to bind as tightly or as long as wildtype ~ and in the presence 
of enzyme and inhibitor only (no substrate) this led to a higher level of trj^psin 
self-hydrolysis. 
Another possibility exists. CMTI-V was isolated as an inhibitor of trypsin, 
i.e., screened against trypsin for identification. However, its major function in 
vivo may not necessarily be as an inhibitor of animal digestive enzymes. 
Inhibitors of serine proteinases have found to serve regulatory as well as defense 
functions (Ryan, 1980). This suggests the approach of screening CMTI-V 
against other enzsnnes perhaps not just serine proteinases) for possible other 
functional roles. It is possible that the fully-conserved P3 Val might be found to 
be important to another, unrelated, function of CMTI-V. 
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GENERAL CONCLUSIONS 
We have studied the P3 and PI' residue positions in an inhibitor of serine 
proteinases isolated from pumpkin seed, CMTI-V. Our resiQts have suggested 
that a negatively-charged side chain at the PI' position is critical to the 
inhibitor's ability to function as an inhibitor rather than a substrate. Our data 
support the previously-suggested model (Laskowski and Kate, 1980) of a non-
flexible inhibitor that binds tightly and is hydrolyzed slowly versus a more 
flexible substrate that is quickly hydrolsrzed and released. Data from studies of 
P3 mutants indicate that although a hydrophobic residue at the P3 position is 
fully conserved, loss of hydrophobicity has little affect on enzyme inhibition 
assays and dissociation constants. However, 24-hour hydrolysis reactions 
suggest that over time, the equilibrium between bound inhibitor and unbound 
inhibitor, which lies toward bound inhibitor in wildtype, lies more toward 
unbound inhibitor in mutants. These results are consistent with the observation 
that the PI' position is intimately involved in the enzyme's cataljrtic mechanism, 
while the PS position is involved in a more general interaction of incresising 
tightness of binding between inhibitor and substrate. 
Some restrictions exist on interpretation of the data, however. For 
example, to calculate the dissociation constant Kj we have used a methodology 
that has been found to be useful in situations where the inhibitor remains 
tightly bound to enzyme, i.e., the effective concentration of inhibitor is decreased 
(Bieth, 1974). Yet our hydrolysis experiments suggest that mutants D45L and 
D45V act as substrates rather than inhibitor, and D45N, V42G, V42M and V42S 
also apparently seem to bind less tightly than does wildt3^e.An additional 
complication is that modifed inhibitor (i.e., hydrolyzed) retains at least some 
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level of activity toward enz3rme. This means that our measurements apply to 
both virgin and modified inhibitor and must be interpreted as such. 
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APPENDIX A. DETAILED METHODOLOGY 
Site-Directed Mutagenesis 
Mutagenic Oligonucleotides and Flanking Primers 
Oligonucleotides were prepared by Keystone Laboratories (Menlo Park, 
CA) and were diluted in water to a concentration of 200 pmol/Ail (Table 26, see 
Tables 7 and 13 for specific mutagenic sequences). The flanking primers used 
were a 3' PTI Primer (Keystone Laboratories, Inc.) and a 5' BAM primer 
(National Biosciences, Hamel, MN) with, the following sequences. 
Table 26. Sequences of flanking primers used for PGR overlap extension 
PRIMER SEQUENCE 
s'pn 5' CGCGGATCCGCGTTAACCGATCCTC 3' 
5* BAM 5' CAATGGATCCTCCTGCCCAGGTAAGTC 3' 
Site directed mutagenesis (Figure 24), consisting of two PCR steps and an 
overlap extension step, involved amplification of target sequences using a 
plasmid with the wild-type (70-1) template delimited by mutagenic and flanking 
primers. 
First PCR Procedure 
Frozen transformed JM109 cells containing wild-type CMTT-V 
recombinant vector were placed in a 50 ml falcon tube with 10 ml of Lennox L 
Broth Base (Gibco BRL) and 100 //g/ml ampidUin. The tube was placed 
overnight on a shaker (200 rpm) at 37° C. Wizard Mini-Preps (Promega, 
Madison, WI) was used to isolate and purify the template plasmid DNA. The 
initial PCR step was in a total reaction volume of 50/J: 
• 100 ng of template DNA 
• IX PCR buffer (lOmM Tris-Hcl, pH 8.3; 50mM KCl) 
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• 0.25 mM mixed dNTPs 
• 1.5 mM MgClg 
• 200 pmole of one of the mutagenic oligomers 
• 200 pmole of the appropriate flanking primer (3' PTE primer with the 
forward oligomer, and 5' Bam primer with the reverse oligomer) 
• Water to 50 (A 
The mixture was incubated at 94°C for five minutes, then held at 80°C 
while 2.5 units of Taq DNA poljnnerase (Cetus-Perkin Elmers, Emeryville, CA) 
were added. Twenty cycles of amplification followed, each cycle consisting of: 
• 94°C for one minute, allowing melting of the double-stranded template 
DNA; 
• 55°C for one minute, allowing annealing of sin^e-stranded template DNA 
to single-stranded oligomers,- and 
• 72 "C for two minutes, allowing extension of primers through the 
incorporation of the dNTPs. 
During the final cycle, the third stage was extended fi:om two minutes to ten 
minutes. 
DNA Isolation Procedure 
Products of PGR Step 1 were analyzed on a 2% agarose gel containing 0.5 
//g/ml ethidium bromide, run in IX TAE buffer. Fragments of the appropriate 
length were identified by comparison witii firagments of a 1Kb Ladder (Gibco-
BRL); the embedding gel was sliced out and the DNA recovered by hand-
pressing of the gel slices wrapped in parafilm pockets. The extruded DNA-
containing liquid was placed in eppendorf tubes and the DNA purified. One 
volxime of N-butanol saturated with T^oEi was added to DNA in an eppendorf 
t 
tube. After vortexing and centrifugation for 1 minute, the top layer was 
disposed of. This was repeated once. One volume of phenol/chloroform was 
added, and this was vortexed, microcentrifiiged for five minutes, and the top 
layer transferred to a firesh eppendorf tube. Afiter addition of an equal volume of 
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chloroform/isoamylalchohol, vortexing, and microcentrifugation for five minutes, 
the top layer was once again transferred to a firesh eppendorf. One-tenth volume 
3M NaOAc (ph 5.6) and two volumes 100% ETOH were added, and after 
vortexing, the mixture was stored at -70 °C for at least one hour, then removed 
and warmed. It was then microcentrifuged for 15 minutes at 4°C 
The supernatant was discarded and 500 (A cold 70% ETOH was added. 
This was microcentrifuged for 5 minutes at 4°C and the procedure was repeated 
two times, and finally the pellet was air dried. It was then dissolved in an 
appropriate volume of water. Presence of DNA was verified by running an 
ahquot of the recovered DNA on a 2% agarose gel. 
Overlap Extension Procedure 
In the second step of the mutagenesis process, firagment pair members 
with overlapping homology were annealed and the 3' ends extended. The 
reaction was done in a total volume of 30 /J: 
• IX annealing buffer 
• Combined pair purified products firom the initial PGR step 
• Water to 30 aJ 
This was incubated at 94°C for three minutes (denatxiration) followed by 
incubation at 55°C for two hours (annealing). Then, added to a final 
concentration of 40 lA: 
• 7.5 mM dithiothreitol (DTT) 
• 2.5 mM dNTPs 
• IX enz3rme dilution buffer (TDB) 
• 1.5 units Klenow enzyme (Amersham) 
• Water to 40 (A 
This was incubated at 37.0°C for 30 minutes. A second extension step 
was done by adding additional dNTTPs, buffer and Klenow, followed by 
incubation for 30 minutes. The appropriate products were gel pxmfied as 
previously described-
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Second PCR Procedure 
In the third and final step of the mutagenesis process purified DNA firom 
the overlap extension step was amplified in a 50 /zl reaction: 
• DNA recovered from tJie overlap extension procedure 
• IX buffer (lOmM Tris-HCl, pH 8.3; 50mM KCl) 
• 0.25mM mixed dNTPs 
• 1.5mM MgCla 
• 3' PTI and Bam primers 
• Water to SOaJ 
Taq polymerase was added as a final step, and the amplification cycle proceeded 
as previously described. The amplified DNA was recovered and purified after 
selecting the appropriately-sized firagments (230 bp) firom a 2% agarose gel. 
Subcloning, Transformation and Sequencing 
The recovered DNA was digested with 20 units Bam HI with IX BamHI 
buffer and Img/ml bovine serum albumin in a total volmne of 20 tA. The 
mixture was incubated at 37°C for three hours. The insert wsis gel purified and 
ligated to pT7-7 by incubating it overnight in a 14°C bath with 200 units of T4 
DNA Hgase (New England Biolabs), pT7-7 precut with BamHI and 
dephosphorylated, and NEB Hgase buffer with 10 mM ATP. 
The recombinant vector was transformed into E. coli strain JM109. One 
hundred [A of competent JM109 cells were incubated with 10 /J. of the Hgation 
mixture on ice for 40 minutes, gently shaking the tube every ten minutes. The 
mixture was heat shocked (42 °C) for exactly two minutes and cooled on ice for 
two to three minutes. This was spread on media plates containing 100 A^g/ml 
ampicillin and incubated overnight at 37°C. 
Single colonies were transferred using sterilized toothpicks to a gridded 
plate with media containing 100 jug/ml ampicillin. The gridded plates were 
incubated several hours at 37°C. Positively-charged colony/plaque screen 
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membranes CDuPont) were used. The membranes were placed over the plates 
for five minutes. Orientation of the media and membrane were marked with a 
20-G needle dipped in India ink. The membranes were lifted and then placed 
colony-side up within a folded, but not compressed, sheet of 3MM paper. After 
air-dr3ring for 15 minutes the membranes were autodaved for foxir minutes. The 
membranes were next washed three times with 4X SSC/1% SDS and then air-
dried. 
The dried membranes were prehybridized for 4 hours at 37°C in a 
solution of 100 Mg/nil herring sperm DNA, 10% dextran sulfate, 25% formamide, 
1% SDS, and 1M NaCl. CMTI-V DNA was labelled using the Multiprime DNA 
LabeUing System (Amersham). After denaturing by boiling for 2 minutes, it was 
incubated for 30 minutes at 37°C with ^^-dCTP, mixed dNTPs, random primer 
and BSA, and Klenow. After verification of incorporation of the labelled 
nucleotide, the probe was denatured once again and added to the 
prehybridization solution. The membranes were placed in this solution and 
hybridized ovemi^t at 37°C. 
The membranes were washed three times, ten minutes each wash, in 2X 
SSC and 1% SDS at room temperature followed by two 5-minute washes with 
0.5XSSC and 1% SDS at 42°C. After blotting the membranes dry on 3MM paper 
they were wrapped in plastic wrap and orientation was marked by small pieces 
of 3MM paper dipped in India ink and ^®S. The membranes were placed in a 
cartridge with X-ray film and left at -20°C for 2.5 hours. Positive colonies 
identified on the autoradiogram were transferred to a second set of gridded 
plates and incubated overnight at room temperature. 
DNA Sequencing 
Plasmids isolated from positive colonies were selected for sequencing. 
Those showing an initial insert in the appropriate orientation subsequently had 
94 
both strand inserts ftdly sequenced. Colonies were grown up overnight in LB 
Broth containing 100 Mg/ml ampidllln and plasmid DNA was isolated using 
Wizard Mini-Preps kit. The presence of plasmid DNA was checked on a 2% 
agarose gel before sequencing using the dideoxynucleotide chain termination 
method (Sanger et al., 1977). Reactions were carried out using one of two 
methods. 
Method 1 
Step 1 • Base Denaturation of Template 
The following were mixed: 
• 40 plasmid DNA (2-3ug) 
• 1/5 volume 2 M NaOH/1 mM EDTA 
and incubated 10 minutes at 37°C before adding; 
• 5 M NH40Ac = 5.6) equal in final concentration to base 
• 2X total volume 100% ice-cold ethanol 
This was mixed well and incubated 15 minutes at -70"C. The DNA was 
precipitated and resuspended in liA water. 
Step 2 • Annealing of Template to Primer 
The following were mixed: 
• Resuspended template DNA 
• IX Sequenase Reaction Buffer 
• T7-7R Far Primer or T7 Primer 
and placed on a 70° C heating block for 1 minute. After removing the block 
containing the mixture &om heating core the block was allowed to cool to below 
35°C 
Step 3 - Synthesis/Labeling 
The following were mixed in an eppendorff tube: 
• labelling mix, diluted 1:5 with water 
• O.IMDTT 
• "'S dATP 
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• DNA Polymerase, diluted 1:8 with TDB buffer 
This was added to the template/primer mix (Step 2) and mixed well, 
followed by incubation at room temperature for 5 minutes. 
Step 4 - Termination 
4.5 lA of reaction mix were added to tubes containing 2.5 [A of either 
ddATP, ddTTP, ddGTP, ddCTP. These were mixed and incubated at for 5 
minutes, followed by the addition of 4 /d stop solution. 
Method 2 fSequenase Quick-Denature Plasmid Sequencing Kit, United States 
Biochemical). 
Step 1 - Glycol/Heat Denaturation of Template 
The following were mixed: 
• up to 7/zl plasmid DNA (2-3ug) 
• 5 /J Plasmid Denaturing Reagent 
• \iA primer 
• H2O to 13 /zl 
and incubated 5 minutes at 90-100°C and then chiUed. 
Step 2 - Annealing of Template to Primer 
Two lA Plasmid Reaction Buffer was added, and the mixture incubated at 
37°C for 10 minutes, then chilled. 
Step 3 - Labeling 
To the chilled mixture, the following were added: 
• 2/J dQute labeling mixture 
• 1//10.1MDTT 
• 0.5 /J '®SdATP 
• 2 ^1 diluted Sequenase Version 2.0 enzyme 
This was incubated at room temperature for 5-10 minutes. 
Step 4 - Termination 
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4.5 lA of reaction mix were added to tubes containing 2.5 (A of either 
ddATP, ddTTP, ddGTP, ddCTP. These were mixed and incubated at 37° C for 5 
minutes, followed by the addition of 4 / J stop solution. 
After sequencing, samples were boiled 2 minutes to denature and then 
loaded onto a gel made &om a filtered solution of 31.5 g urea, 20 mg ammonium 
persulfate, 11.25 ml 40% acrylamide/2% bisacrylamide, 7.5 ml lOX TBE (100 ^1 
TEMED added immediately before pouring). Gels were run for several hours at 
40-50u and after drying, placed next to film and left overnight at -20 °C. 
Sequencing residts were anals^zed using the sequence analysis software "Seqaid" 
(Rhoads and Roufa, 1989). 
Protein Expression 
Vector pT7-7 contains the T7 promoter and is dependent on T7 RNA 
polymerase for target gene expression. The recombinant vector was transformed 
into the E. coli host BL21(DE3) which contains the T7 RNA poljnnerase gene 
under control of the lacZ promoter. The promoter is inducible through the 
addition of isopropyl-l-thio-P-D-galactoside (EPTG). 
A colony of BL21(DE3) cells was used to inoculate 5 ml of LB broth and 
cultured overnight on a shaker (200 rmp) at 37°G. Competent cells were 
prepared as follows. One ml of overnight culture was added to a flask with 50 
ml LB broth and this placed on a shaker at 200 rpm (37°C) for three hours. 
After centrifuging the culture at 5000 rpm for 5 minutes the supernatant was 
discarded and the peUet resuspended in ice-cold CMl, 1/5 culture volume (10 
mM NaOAc, pH5.6, 50 mM MnClg, 5 mM NaCl). This was incubated on ice for 
20 minutes and centrifuged 5 minutes at 5000 rpm, then resuspended in ice-cold 
CM2, 1/50 culture volume (10 mM NaOAc, pH 5.6, 70 mM CaCl2, 5 mM MnClg, 
5% glycerol). One hundred ^1 competent ceUs and 1 fA plasmid DNA were 
placed in a 15 ml falcon tube and mixed well. This was incubated on ice 40 
minutes, with gentle mixing every 10 minutes, and was followed by a heat shock 
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(42 °C) for two minutes and an incubation on ice for 40 minutes. The culture 
was then spread on LB plates with amp/ml and incubated overnight at 
37°C. Cells from one colony containing the recombinant DNA were transferred 
with a sterile toothpick and cultivated overnight in LB broth with 200 y^g/ml 
ampidllin at 37°C on a shaker (200 rpm). The ceU culture was diluted 1:10 and 
then placed once again at 37°C at 200 rpm until an 0 J).600 of 0.6-0.7 reached. 
IPTG (1.5 mM) was then added to the culture and the cultures remained on the 
shaker for an additional four hours. Cells were harvested by centrifiigation at 
4000g for ten minutes at 4''C. The peUet was suspended in ice-cold TiqEj (1/50 
culture volume) and cells were broken by sonication at half maximum speed for 
30 seconds, followed by 30 seconds cooling. This sonication/cooling cycle was 
repeated three times followed by centrifiigation at 4°C for 30 minutes at 4000g. 
The cell-firee extract was stored at -70°C imtil use. SDS-PAGE was used to 
verify over-expression of the protein. An aliquot of the celL-&ee extract was run 
for one hour at 25-30 mA and the gel was stained with Coomassie Brilliant Blue. 
Purification of Inhibitor Protein 
An antibody affinity column with covalently-bound CMTI-V antibody and 
equilibrated with Tris*HCl/NaCl buffer (50 mM Tris.Cl pH8.0/0.2 M NaCl) was 
used to isolate the recombinant protein &om the cell-&ee extracts. Cell &ee 
extract was loaded onto the colimm and the colimm was washed with Tris'HCl 
buffer (7.8 pH). Protein was eluted with 0.2 M glycine CpH2.5), and collected 
fractions were measured on a spectrophotometer at 280 nm. Fractions were 
neutralized by the addition of 2 M Tris«HCl 0)H 8.0) and those fractions with 
increased readings were pooled and concentrated. Concentrated protein solution 
was dialyzed using Spectrapor Molecular Porous Membrane (Spectrum Medical 
Industries, Houston). SDS-PAGE was used to check protein purity. Dialyzed 
protein was placed in a lyophilizer bottle, placed at -70 °C until frozen, and then 
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lyophylized overnight. Dried sample was resxispended in 200-500Ad 10 mM 
Tris-HCl (pH 8.0) and stored at -2Q°Q. 
Hydrolysis Experiments 
Reactions were run overnight at room temperature. Each reaction was 
run at an equal volume of reactants, reaction bu£Eer, and water (modified from 
Longstaff et al, 1990). Controls were run alongside (e.g., enz3mie in reaction 
buffer with no inhibitor added, and inhibitors in reaction buffer with no enzyme 
added. Each set of reactions contained equivalent amounts of inhibitor (e.g., 
wildt57pe inhibitor without and with enzyme). 
Enzyme Inhibition Assays 
The mutgint inhibitors were tested against bovine trypsin (Sigma) and 
human P-Factor Xn^ (Calbiochem) by measuring the residual activity of a given 
proteinase after incubation with inhibitor (Wen et al., 1993). Various amounts 
of inhibitor were mixed with fixed amounts of enzymes in an appropriate 
reaction buffer (for taypsin, 0.1 M Tris-HCl/0.02 M CaCl2, pH=8.2 and for p-
Factor XUg, the same without CaCh and with 20% BSA added). After 
incubation for ten minutes at room temperature, a substrate (final concentration 
of 9.2 mM Na-benzoyl-DL-argLnine p-nitroanilide hydrochloride, BAPNA, 
dissolved in DMSO for trypsin, 4 mM S2302 in water for P-Factor Xlla) was 
added to the mixture and the rate of release of p-nitroanilide was monitored 
using a spectrophotometer at 405 nm. Readings were taken at 20 second 
intervals for 5 minutes. Activity of each mutant inhibitor was compared with 
wild-t3i)e inhibitor in this manner. Results were plotted as percent residual 
activity versus concentration of inhibitor for each enzyme. 
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APPENDIX B. DETAILED DATA 
InMbition Assay Data 
Trypsin Assays with D45 Mutants 
Fi^re 45. Graphs of hydrolysis of the chromogemc 
trypsin substrate N-benzoyl-DL-arginine-P-nitroanilide 
(BAPNA) by bovine trypsin in absence and presence of 
increasing amounts of inhibitor, (a) Wildtype (70-1), (b) 
mutant protein D45L, (c)mutant protein D45V. 
100 
Table 27. Calculation of % residual enzsrme activity in presence of inhibitor and 
dissociation constant (Kj) for 70-1 against trj^sin; £!i=1.4£-08M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
O^g) %Residuai Activity 
9.31E-09 1.56 0.36 2.58E-08 0.08 63.92 
2.79E-08 1.43 0.30 9.34E-08 0.23 70.11 
4.65E-08 2.12 0.53 8.8E-08 0.38 47.14 
6.98E-08 4.11 0.76 9.22E-08 0.57 24.32 
9.31E-08 4.86 0.79 1.17E-07 0.76 20.58 
'a is the firaction of unbound enz)^e as defined by Bieth 1974. 
Table 28. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) fQrD45L against trypsin; Ei=9.0E-07M. 
[Inhibitor] 
(molar) 1/a^ 1-a [I]/l-a 
[Inhibitor] 
(ug) 
%Residuai 
Activity 
2.26E-07 1.63 0.39 5.81E-07 1.84 61.18 
6.77E-07 2.59 0.61 l.lE-06 5.51 38.57 
1.13E-06 3.16 0.68 1.65E-06 9.19 31.60 
2.26E-06 4.30 0.77 2.94E-06 18.38 23.23 
3.39E-06 5.74 0.83 4.1E-06 27.57 17.40 
'a is the firaction of unbound enzyme as defined by Bieth, 1974. 
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Table 29. Calculation of % residual enz3mie activity in presence of inhibitor and 
dissociation constant (K;) for D45V against taypsin; Kj=1.2E-06M. 
[Iniubitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
C"g) 
%Residual 
Activity 
1.05E-07 1.22 0.18 5.73E-07 0.86 81.67 
5.25E-07 1.65 0.39 1.33E-06 4.28 60.57 
1.05E-06 1.89 0.47 2.23E-06 8.55 52.87 
1.58E-06 2.63 0.62 2.54E-06 12.83 38.03 
2.1E-06 3.14 0.68 3.08E-06 17.104 31.83 
is the fraction of unbound enzyme as defined by Bieth, 1974. 
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Figure 46. Plots of data firom Tables 27-29. Slope of the lines are the 
dissociation constant (Ki). (a) Wildtype (70-1), 1.4E-08M, (b) mutant 
protein D45L, 9.0E-07M; (c)mutant protein D45V, 1.2E-06M. 
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Figure 47. Graphs of hydrolysis of the chromogenic 
trjrpsin substrate N-benzoyl-DL-arginine-P-nitroanilide 
(BAPNA) by bovine trypsin in absence and presence of 
increasing amounts of inhibitor, (a) Wildtype (70-1), 
(b) mutant protein D45E, (c)mutant protein D45N. 
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Table 30. Calculation of % residual enzsmie activity in presence of inhibitor and 
dissociation constant (Kj) for 70-1 against trypsin; Ki=2.2E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a m/i-a 
{Inhibitor] 
(Mg) 
%ilesidual 
Activity 
4.94E-09 2.11 0.53 9.38E-09 0.04 47.37 
1.48E-08 1.54 0.35 4.2E-08 0.12 64.78 
2.96E-08 3.85 0.74 4.0E-08 0.24 25.97 
3.95E-08 49.11 0.98 4.03E-08 0.32 2.04 
'a is the is the firaction of unbound enzyme defined by Bieth, 1974. 
Table 31. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (K^) for D45E against trypsin; Ki=1.5E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(Mg) 
% Residual 
Activity 
3.22E-09 1.56 0.36 8.92E-09 0.03 63.92 
9.65E-09 5.75 0.83 1.17E-08 0.08 15.27 
1.29E-08 6.55 0.85 1.52E-08 0.10 15.27 
1.93E.08 9.93 0.90 2.15E-08 0.16 10.07 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
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Table 32. Calcvilatioa of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for D45N against trypsin; Ki=amdetermined 
[Inhibitor] 
(molar) 1/a' 1-a [TJ/l-a 
[Inhibitor] 
O^g) 
%Residual 
Activity 
2.23E-07 1.48 0.32 6.91E-07 1.82 67.67 
4.47E-07 1.84 0.46 9.76E-07 3.64 54.22 
6.7E-07 9.76 0.90 7.47E-07 5.46 10.24 
8.94E-07 5.62 0.82 1.09E-06 7.28 17.78 
'a is the fraction of unbound enzyme determined by Bieth, 1974. 
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Figure 48. Plots of data &om Tables 30-32. Slope of the lines are the 
dissociation constant (Ki). (a) wildt3T)e (70-1), 2.2E-10; (b) mutant 
protein D45E, 1.5E-09M; and (c)mutant protein D45N, undetermined. 
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Figure 49. Graphs of hydrolysis of the chromogenic 
trypsin substrate N-benzoyl-DL-arginine-P-mtroamlide 
(BAPNA) by bovine trypsin in absence and presence of 
increasing amounts of inhibitor, (a) WUdtype (70-1), 
(b) mutant protein D45E, (c)mutant protein D45N. 
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Table 33. Calculation of % residual enzjone activity in presence of inhibitor and 
dissociation constant (Ei) for 70-1 against trypsin; Ki=4.3£-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
O^g) 
%Residual 
Activity 
l.OE-09 1.29 0.22 3.23E-09 0.01 77.63 
4.0E-09 1.51 0.34 1.07E-08 0.03 66.25 
7.0E-09 2.04 0.51 1.42E-08 0.06 49.14 
l.lE-08 2.17 0.54 2.01E-08 0.09 46.00 
1.4E-08 4.13 0.76 1.91E-08 0.12 24.21 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
Table 34. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for D45E against trypsin; Kj=3.6£-09M. 
[Inhibitor] 
(molar) Ha} 1-a [I]/l-a 
[Inhibitor] 
(ms) 
% Residual 
Activity 
4.69E-10 1.10 0.09 5.17E-09 0.004 90.93 
6.57E.09 1.81 0.45 1.47E-08 .05 55.38 
1.17E-08 2.89 0.65 1.79E-08 0.10 34.60 
1.88E-08 5.42 0.82 2.3E-08 0.15 18.47 
'a is the fraction of unbound enzyme as defined by Bieth, 1974. 
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Table 35. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for D45N against trypsin; Ei=undetermined. 
[Inhibitor] 
(molar) Ha} 1-a m/i-a 
[Inhibitor] 
O^g) 
% Residual 
Activity 
3.74E-09 1.28 0.22 1.72E-08 1.82 67.67 
5.62E-09 1.16 0.13 4.17E-08 3.64 54.22 
1.12E-08 1.30 0.23 4.86E-08 5.46 10.24 
2.25E-08 1.15 0.13 1.73E-07 7.28 17.78 
'a is the fraction of unbound enzyme as defined by Bieth, 1974. 
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Figure 50. Plots of data from Tables 33-35. Slope of the lines are 
the dissociation constant (Ki). (a) Wildtype (70-1), 4.3E-09M, (b) 
mutant protein D45E, 3.6E-09M, (c)mutant protein D45N, 
undetermined. 
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Figure 51. Graphs of hydrolysis of the 
chromogenic siibstrate, S2302, by {3-Factor XQ, in 
absence and presence of increasing amounts of 
inhibitor, (a) Wildtype (70-1), (b) mutant protein 
D45L, (c)mutant protein D45V. 
112 
Table 36. CaLculation of % residual enz3mie activity in presence of inhibitor and 
dissociation constant (IQ for 70-1 against P-Factor ioi,; Ki=1.4£-08M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] %llesidual 
Activity 
9.31E-09 1.32 0.24 3.84E-08 0.08 75.78 
4.65E-08 2.86 0.65 7.16E-08 0.38 34.99 
7.45E-08 3.59 0.72 1.03E-07 0.61 27.83 
1.12E-07 5.29 0.81 1.38E-07 0.91 18.90 
1.68E-07 11.42 0.91 1.84E-07 1.36 8.76 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
Table 37. Calculation of % residual enzjrme activity in 
dissociation constant (Kj) for D45L against P-Factor XII, 
presence of inhibitor and 
Ki=2^-07M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
Cug) 
% Residual 
Activity 
2.26E-07 2.83 0.65 3.49E-07 1.84 35.36 
6.77E-07 4.89 0.80 8.51E-07 5.51 20.47 
1.13E-06 6.61 0.85 1.33E-06 9.19 15.12 
1.69E-06 11.24 0.91 1.86E-06 13.79 8.90 
2.26E-06 8.90 0.89 2.54E-06 18.38 11.23 
is the fraction of unbound enzyme defined by Bieth, 1974. 
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Table 38. Calculation of % residual enzjnne activity in presence of inhibitor and 
dissociation constant (Kj) for D45V against P-Factor XHaJ Ki=5.3E-07M. 
[Inhibitor] 
(molar) Ha} 1-a m/i-a 
[Inhibitor] 
O^g) %£esidual Activity 
1.05E-07 1.74 0.42 2.47E-07 0.86 57.56 
3.15E-07 3.16 0.68 4.61E-07 2.57 31.64 
5.25E-07 2.24 0.55 9.47E-07 4.28 44.57 
1.05E-06 3.78 0.74 1.43E-06 8.55 26.46 
1.58E-06 4.62 0.78 2.01E-06 12.828 21.63 
is the fraction of unbound enzyme defined by Bieth, 1974. 
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Figure 52. Lots of data firom Tables 36-38. Slope of the Unes are the 
dissociation constant (Ki). (a) Wildt3i)e (70-1), 1.4E-08M; (b) D34L, 
2.2E-07; and (c)D45V, 5.3E-07M. 
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Figure 53. Graphs of hydrolysis of the chromogenic 
substrate, S2302, by P-Factor XII, in absence and 
presence of increasing amounts of inhibitor, (a) 
Wildtype (70-1), (b) mutant protein D45L, (c)mutant 
protein D45V. 
116 
Table 39. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (K;) for 70-1 against P-Factor XUa; K,—1.3E-08M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(MS) 
%Residual 
Activity 
1.49E-06 1.28 0.22 6.78E-08 0.12 78.04 
4.47E-06 2.82 0.65 6.92E-08 0.36 35.41 
7.45E-08 3.47 0.71 1.05E-07 0.61 28.79 
1.19E-07 6.49 0.85 1.41E-07 0.97 15.41 
1.79E-07 11.53 0.91 1.96E-07 1.46 8.67 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
Table 40. Calculation of % residual enz3nne activity in presence of inhibitor and 
dissociation constant (Kj) for D45L against P-Factor Xlla; Ki=3.5E-07M. 
[Inhibitor] 
(molar) 1/a^ 1-a [I]/l-a 
[Inhibitor] 
(ms) 
% Residual 
Activit>' 
5.68E-08 1.09 0.08 6.92E-07 0.46 91.80 
1.14E-07 1.24 0.19 5.92E-07 0.92 80.81 
2.27E-07 1.39 0.28 8.04E-07 1.85 71.75 
6.81E-07 2.00 0.50 1.36E-06 5.55 49.90 
1.14E-06 3.76 0.73 1.55E-06 9.25 26.63 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
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Table 41. Calciilation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for D45V against P-Factor Xn,; Ki=1.3E-07M. 
[Inhibitor] 
(molar) 1/a' 1-a m/i-a 
[Inhibitor! 
(wg) 
%Residual 
Activity 
2.21E-08 1.33 0.25 8.89E-08 0.18 75.14 
4.24E-08 1.12 0.11 4.1E-07 0.36 89.21 
l.llE-07 1.30 0.23 4.8E-07 0.90 76.99 
2.21E-07 1.89 0.47 4.68E-07 1.80 52.79 
4.42E-07 3.40 0.71 6.26E-07 3.6 29.44 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
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Figure 54. Plots of data from Tables 39-41. Slope of the Imes are the 
dissociation constant (Ki). (a) Wildtype (70-1), 1.3E-08M; (b) D45L, 
3.5E-07; (c)D5V, 1.3E-07. 
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Figure 55. Graphs of hydrolysis of the chromogenic 
substrate, S2302, by P-Factor Xlla in absence and 
presence of increasing amounts of inhibitor, (a) 
Wildtype (70-1), (b) mutant protein D45E, (c)mutant 
protein D45N. 
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Table 42. Calculation of % residual enzjone activity in presence of inhibitor and 
dissociation constant (K;) for 70-1 against P-Factor Xn,; Ei=8.4E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(ug) 
% Residual 
Activity 
4.54E-10 3.33 0.70 6.49E-10 0.01 30.04 
1.36E-09 4.36 0.77 1.77E-09 0.01 22.97 
2.27E-09 3.41 0.71 3.21E-09 0.02 29.30 
3.18E-09 5.61 0.82 3.84E-09 0.03 17.83 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
Table 43. Calculation of % residual enz3nne activity in presence of inhibitor and 
dissociation constant (Kj) for D45E against P-Factor XTEa,' Ei=4.lE-08M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l.a 
[Inhibitor] 
(ug) 
^Residual 
Activity 
2.29E-08 1.52 0.34 6.69E-08 0.19 65.78 
4.01E-08 2.25 0.55 7.22E-08 0.33 44.52 
8.01E-08 2.45 0.59 1.35E-07 0.65 40.83 
1.2E-07 3.90 0.74 1.62E-07 0.98 25.61 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
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Table 44. Calculation of % residual enzjone activity in presence of inhibitor and 
dissociation constant (Kj) for D45N against P-Factor Xlla; Ei=3.4E-08M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
O^g) %Residual Activity 
2.21E-08 1.70 0.41 5.4E-08 0.18 59.11 
LllE-07 3.06 0.67 1.64E-07 0.9 32.66 
2.65E-07 5.84 0.83 3.2E-07 2.16 17.11 
6.63E-07 19.55 0.95 6.99E-07 5.4 5.12 
is the firaction of unbound enzyme defined by Bieth, 1974. 
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Figure 56. Plots of data &oin Tables 42-44. Slope of the lines are the 
dissociation constant (Ki). (a) Wildtype (70-1), 8.4E-10M; (b) D45E, 
4.1E-08; (c)D45N, 3.4E-08M. 
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Figure 57. Graphs of hydrolysis of the 
chromogenic substrate, S2302, by P-Factor Xn, in 
absence and presence of increasing amounts of 
inhibitor, (a) Wildtype (70-1), (b) mutant protein 
D45E, (c)mutant protein D45N. 
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Table 45. Calculation of % residual enz3mie activity in presence of inhibitor and 
dissodatLon constant (K;) for 70-1 against ^ -Factor XUa; Ei=3.2E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [IJ/l-a 
[Inhibitor] 
O^g) 
%Residual 
Activity 
7.23E-10 1.23 0.19 3.81E-09 0.01 81.03 
2.17E-09 1.39 0.28 7.73E-09 0.02 71.95 
3.62E-09 1.89 0.47 7.66E-09 0.03 52.80 
5.79E-09 2.58 0.61 9.44E-09 0.05 38.74 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
Table 46. Calculation of % residual enzjnne activity in presence of inhibitor and 
dissociation constant (EQ for D45E against P-Factor Xn,; Ki=€.2E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(Mg) 
% Residual 
Activity 
2.35E-09 1.37 0.27 8.74E-09 0.02 73.15 
7.04E-09 2.26 0.56 1.26E-08 0.06 44.26 
1.17E-08 3.04 0.67 1.75E-08 0.10 32.95 
1.64E-08 3.61 0.72 2.27E-08 0.13 27.74 
is the fraction of unbound enzjone defined by Bieth, 1974. 
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Table 47. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant for D45N against P-Factor XTE,; Ki=3.1E-08M. 
[Inhibitor] 
(molar) 1/a' 1-a Pl/l-a 
[Inhibitor] %Residual 
Activity 
3.74E-09 1.21 0.18 2.13E-08 0.03 82.46 
7.49E-09 1.53 0.34 2.17E-08 0.06 65.45 
1.12E-08 1.60. 0.37 3.0E-08 0.09 62.60 
1.87E-08 1.84 0.46 4.11E-08 0.15 54.41 
'a is the fi:action of unbound enz)rme defined by Bieth, 1974. 
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Figure 58. Plots of data from tables 45-47. Slope of the Hnes are the 
dissociation constant (Ki). (a) Wildtype (70-1), 3.2E-09M; (b) D45E, 6.2E-
09; (c)D45N, 3.1E-08. 
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Trypsin Assays with D42 Mutants 
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Figure 59. Graphs of hydrolysis of the 
chromogenic trypsin substrate N-benzoyl-DL-
arginine-P-nitroanilide (BAPNA) by bovine 
trypsin in absence and presence of increasing 
amounts of inhibitor, (a) Wildtjrpe (70-1), (b) 
mutant protein V42G, (c)mutant protein V42M, 
(d) mutant protein V42S. 
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Table 48. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42G against taypsin; Ki=4.1E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
Cwg) 
% Residual 
Activity 
8.01E-09 1.69 0.41 1.96E-08 0.06 59.18 
1.6E-08 3.34 0.70 2.28E-08 0.13 29.91 
2.4E-08 6.13 0.84 2.87E-08 0.20 16.32 
3.2E-08 28.89 0.96 3.32E-08 0.26 3.46 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
Table 49. Calculation of % residual enzjone activity in presence of inhibitor and 
dissociation constant (Kj) for V42M against trypsin; Ki=2.3E-10M. 
(Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] %Residual 
Activity 
5.16E-09 1.50 0.33 1.54E-08 0.04 66.56 
1.38E-08 2.52 0.60 2.28E-08 0.11 39.62 
2.41E-08 28.55 0.96 2.49E-08 0.20 3.5 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
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Table 50. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42S against trypsin; Ki=8.1E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a m/l-a 
[Inhibitor] 
O^g) 
%ResiduaI 
Activity 
4.22E-08 2.04 0.51 8.27E-09 0.03 48.90 
8.45E-09 11.17 0.91 9.28E-09 0.07 8.95 
1.69E-08 4.82 0.79 2.13E-08 0.14 20.75 
2.53E-08 12.68 0.92 2.75E-08 0.21 7.89 
'a is the firaction of unbound enzyme defined by Bieth, 1974. 
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Figure 60. Plots of data from Tables 48-50. Slope of the lines 
are the dissociation constant (Ki). (a) Wildtype (70-1), 2.2E-
lOM; (b) V42G. 4.1E-10M; (c)V42M, 2.3E-10M; (d) V42S, 8.1E-
lOM. 
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Figure 61. Graphs of hydrolysis of the chromogenic 
trypsin substrate N-benzoyl-DL-arginine-P-
nitroanilide (BAPNA) by bovine trypsin in absence 
and presence of increasing amounts of inhibitor, (a) 
Wildtype (70-1), (b) mutant protein V42G, (c)mutant 
protein V42M, (d) mutant protein V42S. 
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Table 51. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (E^) for V426 against trypsin; Ei=2.lE-09M. 
[Inhibitor] 
(molar) 1/a' 1-a m/i-a 
[Inhibitor] (Mg) %Residual Activity 
L19E-09 1.20 0.16 7.22E-09 0.01 83.54 
3.57E-09 1.44 0.31 1.16E-08 0.03 69.32 
5.94E-09 2.12 0.50 1.18E-08 0.05 49.54 
1.19E-08 4.31 0.77 1.55E-08 0.10 23.19 
^a is the firaction of unbound enzjone defined by Bieth, 1974. 
Table 52. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42M against trypsin; Ki=6.6E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] (ug) %Residual Activity 
2.53E-09 1.50 0.33 7.6E-09 0.02 66.68 
7.6E-09 1.6 0.38 2.02E-08 0.06 62.43 
1.27E-08 2.02 0.50 2.51E-08 0.10 49.54 
2.53E-08 2.63 0.62 4.08E-08 0.21 38.00 
3.8E-08 27.7 0.96 3.94E-08 0.31 3.61 
is the firaction of unbound enzyme defined by Bieth, 1974. 
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Table 53. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42S against trypsin; Ki=7.2E-10M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(Mg) 
% Residual 
Activity 
1.43E-09 1.24 0.20 7.3E-09 0.01 80.40 
4.29E-09 2.01 0.50 8.55E-09 0.04 49.82 
T.loE-Oe 2.81 0.64 l.llE-08 0.06 35.51 
1.43E-08 11.62 0.91 L57E-08 0.12 8.60 
'a is the firaction of unbound enzj^e defined by Bietb, 1974. 
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Figure 62. Plots of data from Tables 51-53. Slope of the lines are 
the dissociation constant (Ki). (a) Wildtype (70-1), 4.3E-09M, (b) 
V42G, 2.1E-09M, (c)V42M, 6.6E-10M, (d) V42S, 7.2E-10M. 
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P-Factor Xlla Assays with D42 Mutants 
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Figure 63. Graphs of hydrolysis of the chromogenic 
substrate, S2302, by p-Factor Xn^ ia absence and 
presence of increasing amounts of inhibitor, (a) 
Wildtype (70-1), (b) mutant protein V42G, (c)mutant 
protein V42M, (d) mutant protein V42S. 
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Table 54. Calculation of % residual enzsone activity in presence of inhibitor and 
dissociation constant CKj) for V42G against P-Factor Xn^; Ki=2.5E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(Mg) 
%Residual 
Activity 
2.0E-09 2.30 0.56 3.55E-09 0.02 43.58 
6.0E-09 4.02 0.75 7.99 0.05 24.86 
l.OE-08 6.47 0.84 1.18E-08 0.08 8.81 
1.4E-08 5.19 0.81 1.74E-08 0.11 19.27 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
Table 55. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42M against P-Factor XUg; Ki=1.2E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a [I]/l-a 
[Inhibitor] 
(Mg) 
%ResiduaI 
Activity 
3.44E-09 4.05 0.75 4.56E-09 0.03 24.66 
1.2E-08 6.99 0.86 1.4E-08 0.10 14.30 
2.41E-08 19.98 0.95 2.53E-08 0.20 5.00 
^a is the firaction of unbound enzyme defined by Bieth, 1974. 
Table 56. Calculation of % residual enzjnne activity in presence of inhibitor and 
dissociation constant (Kj) for V42S against P-Factor Xlla; Ki=l,9E-9M. 
[Inhibitor] 
(molar) 1/a' 1-a [IJ/l-a 
[Inhibitor] 
(Mg) 
%Residual 
Activity 
4.22E-09 4.11 0.76 5.58E-09 0.03 24.31 
6.63E-09 3.50 0.71 9.28E-09 0.05 28.53 
2.21E-08 12.50 0.92 2.4E-08 0.18 8.00 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
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Figure 64. Plots of data firom Tables 54-56. Slope of the lines are 
the dissociation constant (Ki). (a) Wildtype (70-1), 8.4E-10M, (b) 
V42G, 2.5E-09M, (c)V42M, 1.2E-09, (d) V42S, 1.9E-9. 
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Figure 65. Graphs of hydrolysis of the 
chromogenic substrate, S2302, by P-Factor XELa in 
absence and presence of increasing amounts of 
inhibitor, (a) Wildtype (70-1), (b) mutant protein 
V42G, (c)mutant protein V42M, (d) mutant protein 
V42S. 
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Table 57. CalciQatioii of % residual enzjnne activity in presence of inhibitor and 
dissociation constant (K,) for V42G against p-Factor XEEg; Ki=7.8E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a PJ/l-a 
[Inhibitor] 
O^g) 
%Residual 
Activity 
1.19E-09 1.07 0.06 1.89E-08 0.01 93.72 
5.94E-09 1.58 0.37 1.62E-08 0.05 63.36 
1.19E-08 2.11 0.53 2.26E-08 0.10 47.42 
1.78E-08 2.5 -.60 2.97E-08 0.14 39.98 
'a is the fiiaction of unbound enzyme defined by Bieth, 1974. 
Table 58. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42M against P-Factor XEEaJ Ki=4.2E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a PJ/ l -a  
[Inhibitor] (Mg)  
%Residual 
Activity 
2.Q3E-09 1.31 0.24 1.07E-08 0.02 76.31 
6.33E-09 1.72 0.42 1.52E-08 0.05 58.28 
1.27E-08 2.82 0.75 1.96E-08 0.10 35.40 
1.77E-08 4.15 0.56 2.33E-08 0.14 24.09 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
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Table 59. Calculation of % residual enzyme activity in presence of inhibitor and 
dissociation constant (Kj) for V42S against P-Factor XEEa; Ki=2.8E-09M. 
[Inhibitor] 
(molar) 1/a' 1-a m/i-a 
[Inhibitor] 
("g) 
%Re9idual 
Activity 
1.43E-09 1.44 0.30 4.72E-09 0.01 69.68 
4.29E-98 2.35 0.57 7.47E-09 0.04 42.52 
7.15E-09 2.98 0.66 1.08E-08 0.06 33.53 
l.OE-08 4.43 0.77 1.29E-08 0.08 22.57 
'a is the fraction of unbound enzyme defined by Bieth, 1974. 
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Figure 66. Plots of data from Tables 57-59. Slope of the lines are 
the dissociation constant (Ki), (a) Wildtype (70-1), 3.2E-09M, (b) 
V42G, 7.8E-09M, (c)V42M, 4.2E-09M, (d) V42S, 2.8E-09M. 
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